Estimation of Preanalytical Uncertainty in Clinical Chemistry by Sylte, Marit Sverresdotter
 Estimation of Preanalytical 
Uncertainty in Clinical Chemistry 
Marit Sverresdotter Sylte 
 
Dissertation for the degree philosophiae doctor (PhD)  
at the University of Bergen, Norway 
 
2013 
2 
 
Scientific environment 
This work was carried out at Laboratory of Clinical Biochemistry, Haukeland 
University Hospital, Bergen, Norway and Department of Clinical Science, Faculty of 
Medicine and Dentistry, University of Bergen, Norway under supervision of Professor 
Bjørn J. Bolann, in close collaboration with co-supervisor Bio-statistician Tore 
Wentzel-Larsen at the Centre for Clinical Research, Haukeland University Hospital, 
Bergen, Norway, Norwegian Centre for Violenced and Traumatic Stress Studies, Oslo, 
Norway, Centre for Child and Adolescent Mental Health, Eastern and Southern 
Norway, Oslo, Norway. 
 
 
 
 
 
 
 
 
 
3 
 
The quality of your life is in direct proportion to the amount of uncertainty you can 
comfortably live with. 
Tony Robbins (1960 -) 
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Abstract 
Preanalytical uncertainty is attributable to variations in blood sample collection and 
sample handling before analysis. The aim of this study was to establish a modelling 
framework for estimating preanalytical uncertainty. There is a need for standardization 
on which uncertainty sources that should be included, and how the preanalytical 
uncertainty should be estimated. In Paper I, an uncertainty budget was established 
based on differences in paired data between a standard method for handling blood 
samples and alternative methods used in current practice, considering the distribution 
of alternative methods. In Paper II and III, linear mixed-effects models were used to 
estimate the between-venipuncture SD, the preanalytical SD (excluding the between-
venipuncture SD), and the measurement repeatability when the phlebotomy and the 
sample handling were performed optimally, and any difference in preanalytical SD and 
fixed effects, between transporting blood samples in a pneumatic tube system vs 
manual delivery, using different needles or tubes, and mixing methods. When the 
combined biases from the uncertainty budget in Paper I and the significant biases 
between different treatments in Paper II and III were compared with defined quality 
specifications for analytical bias, glucose was the only analyte falling outside the 
quality specifications. Prolonged clotting and storage time were the greatest 
contributors to the bias for glucose, and the significant mean difference between SST 
vs RST tubes shows that choice of tube is important. The preanalytical SDs (excluding 
the between-venipuncture SD) for LD and potassium for optimally treated samples, 
were significantly higher than the measurement repeatability SDs, but for glucose, the 
between-venipuncture SD was the dominant source of variation. For most analytes, the 
preanalytical SDs were about the same in both studies II and III, indicating that the 
preanalytical variations are little influenced by different preanalytical handling. We 
have developed two models that can be used to estimate preanalytical uncertainty in 
clinical chemistry laboratories. Estimation of preanalytical uncertainty may improve 
diagnostic quality and patient treatment. 
12 
 
List of publications 
This thesis is based on the following original papers, referred to in the text by their 
Roman numerals. 
 
Paper I 
A model for an uncertainty budget for preanalytical variables in clinical chemistry 
analyses.                         
*Rynning M, Wentzel-Larsen T, Bolann BJ. Clinical Chemistry (2007) 53:1343-1348. 
*Change of name to Sylte. 
 
Paper II  
Estimation of the minimal preanalytical uncertainty for 15 clinical chemistry analytes. 
Sylte, MS, Wentzel-Larsen, T, Bolann BJ. Clinical Chemistry (2010) 56:1329-1335. 
 
Paper III  
Random variation and systematic error caused by various preanalytical variables, 
estimated by linear mixed-effects models. 
Sylte, MS, Wentzel-Larsen, T, Bolann BJ. Clinica Chimica Acta (2013) 415:196-201. 
 
 
13 
 
1. INTRODUCTION 
The uncertainty of the result of a measurement reflects the lack of exact knowledge of 
the value of the measurand (1). All test results produced in clinical chemistry 
laboratories are encumbered by uncertainty, and are estimates of true values. 
Knowledge of the result variability is required if results are to be meaningfully 
compared with previous results from the same patient, or with clinical decision limits 
(2).  
A laboratory mistake can be any defect during the entire testing process, from ordering 
the tests to reporting the test results (3). A study on the frequency and types of 
mistakes in a laboratory found that 68% was caused by preanalytical mistakes, 13% by 
analytical mistakes, and 19% by postanalytical mistakes (3). In the preanalytical phase 
samples could be exposed to mistakes such as misidentification of patients and 
specimens, blood collections could be performed by personnel less skilled, specimen 
material could be wrong, samples could be missing, and quantity and quality of the 
specimen could be inappropriate (4). Misidentification of the patient is a serious 
mistake that may result in wrong medical treatment for the patients involved.  
If a series of blood samples is collected over time from one individual for a particular 
laboratory test, the results will vary randomly (5). This random variation consists of 
intra-individual biological variation, preanalytical variation and analytical variation. 
The intra-individual biological variation, also called within-subject variation, causes a 
random fluctuation around a homeostatic setting point due to natural biological factors 
(5). In addition, physiological factors such as age, activity before sampling, food 
ingestion, menstrual cycle, the patients’ posture during the phlebotomy, pregnancy, 
smoking, and the time of the day for the collection may also influence test results (6).  
Measurement uncertainty should not be confused with production error or mistake (7). 
In laboratory medicine, uncertainty sources are commonly grouped as affecting the 
premeasurement, measurement and postmeasurement phases (2). Basic knowledge of 
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implementation, verification, and maintenance of laboratory equipment is essential for 
producing accurate and precise test results (8). Possible changes in test results should 
reflect the changes within the patient, and not represent changes in the trueness or in 
the imprecision of the method (5). A possible bias should not move the patient from 
one diagnosis group to another (9). Automation, standardization and technical 
development have significantly improved the analytical quality and reliability of 
laboratory results (4). The trueness and analytical precision of analyzing methods are 
known and verifiable for most analytes. Technological advances such as barcode 
technology, primary tube processing, serum indices, delta check technology, and 
volume/clotting/bubbles sensors, have increased the quality of test results (10).  
The phlebotomy itself, type of device used to collect the blood, handling of the 
samples after the collection, transport and storage of the specimens may influence the 
measured concentration of components in blood (11). Preanalytical handling demands 
detailed knowledge about recommended tourniquet time, choice of tube, filling and 
mixing, clotting time, centrifugation speed and time, transport, and storage. Since 
premeasurement uncertainties have been difficult to estimate, common practice has 
been to minimize, where possible, the uncertainties by implementing standardized 
procedures for specimen collection, and handling of the blood samples (2).  
There are several evidence-based guidelines in laboratory medicine covering topics 
within both preanalytical, analytical, and postanalytical elements (12). Guidelines 
should be based on the critical evaluation and systematic review of literature, and 
explicitly state the strenght of evidence supporting each recommendation (12). An 
international organization provides consensus guidelines and standards for patient 
testing and health care services, and several standards give descriptive and stepwise 
procedures for improving preanalytical handling of blood samples (6;13-15).  
In laboratory medicine, even if there is substantial emphasis on how different 
preanalytical and analytical factors influence test results, the total uncertainty of test 
results, where both the preanalytical and analytical uncertainty are combined, for most 
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biochemical components is unknown. In a collective paper with synopsis of lectures 
from a conference in preanalytical phase, different preanalytical errors and strategies 
to increase the quality are discussed (16), but estimating the preanalytical uncertainty 
is not emphasized.  
Sampling is part of nearly all chemical measurement. It has been argued that the 
uncertainty caused by sampling has been ignored, and that sampling protocols are not 
validated compared with analytical methods (17). Knowledge of both sampling and 
analytical uncertainty is necessary, in order to make the correct decisions on the test 
results, and to ensure that resources are distributed optimally (17). The fundamental 
sampling error is stated to be the minimum error of an ideal sampling procedure (18). 
It is proposed that the total sampling error can be divided into errors of incorrect 
sampling and errors of correct sampling. Incorrect sampling error causes biases and 
increases the total variance in a unpredictable way, and trying to estimate it would give 
estimates that cannot be generalized. Errors of correct sampling may be quantified as 
measurement uncertainty arising from four sources of errors, the sampling and 
analytical precision, and the sampling and analytical bias (18). 
According to ISO standard 15189 for accreditation, the uncertainty of results should be 
estimated when it is relevant and possible (19). Estimating the preanalytical 
uncertainty is a challenge because the blood samples are exposed to many different 
treatments in current practice, although there are recommended procedures for optimal 
treatment. As a result of this complexity, estimation of preanalytical uncertainty 
demands a model that can estimate both random variations and systematic deviations 
caused by the different preanalytical treatments. Identification of the factors that 
contribute to the variability of repeated measurements results, may provide valuable 
insights into the reliability of results, and potential means for improvement (2).  
In several preanalytical studies, the effect of preanalytical variables was estimated as 
systematic deviations between a specific preanalytical handling practice, and different 
alternative practices (20-22). Some researchers have estimated the preanalytical 
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variation for a specific preanalytical practice, without distinguishing between random 
and systematic effects (23-25). The combined uncertainty for glucose, including the 
uncertainty from patient preparation, position of the patient, sampling and the 
measurement procedure, was estimated based on assumptions of plausible intervals 
and rectangular distributions (26). In another study, paired data were used to calculate 
the uncertainty from specimen collection, effect of delay in pretreatment phase and 
transportation (27). The preanalytical uncertainty components from the different 
experiments, were combined with data on analytical variation, and biological variation 
(27). Some researchers combined the standard uncertainties from the measurement, 
preanalytical variation and intra-biological variation (28). In this study, the uncertainty 
components were quantified using observations of the measuring system, and 
information from calibration certificates, instrument specifications and literature (28).  
To assess the reliability of a test result, and to compare test results with each other, a 
generally accepted procedure for evaluating and expressing the uncertainty is desirable 
(1). There is a need for standardization on which uncertainty sources that should be 
included in the preanalytical uncertainty, how the preanalytical uncertainty should be 
estimated, and what the assumptions are. 
This thesis introduces two models that can be used by the laboratories to estimate 
preanalytical uncertainty for biochemical components. In the following, the 
introduction includes some theory of uncertainty, and a description of the preanalytical 
variables involved in our studies. 
1.1 Random and systematic error 
Traditionally, we differentiate between random and systematic errors. Error is defined 
as “measured quantity value minus a reference quantity value” (7).  
Random measurement error is defined as the “component of measurement error that in 
replicate measurements varies in an unpredictable manner” (7). The random errors are 
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caused by many variables both in the preanalytical and the measurement process. In 
the preanalytical process they may be caused by variation in the phlebotomy, clotting 
time, centrifugal force, storage conditions, transport of the samples, etc.  
Systematic measurement error is defined as a “component of measurement error that in 
replicate measurements remains constant or varies in a predictable manner” (7). The 
systematic measurement error, and its causes, can be known or unknown. Systematic 
deviations, also called biases, influence the test results, and push the test result in one 
definite direction. Over a period of time, some short-term biases may be regarded as 
random variation (2). A correction can be applied to compensate for a known 
systematic measurement error. In preanalytical treatment, a systematic error can be 
introduced as a result of treating the blood samples differently than recommended, 
such as expanding the clotting time, using other tubes than the standardized one, and 
choosing another way of transport. 
Measurement repeatability (the within-run precision) is defined as “measurement 
precision under a set of repeatability conditions of measurement” (7). The repeatability 
precision  is defined as “condition of measurement that includes the same 
measurement procedure, operators, measuring system, operating conditions and same 
location, and replicate measurements on the same or similar objects over a short period 
of time” (7). Measurement reproducibility (the between-day precision) is defined as 
“measurement precision under reproducibility conditions of measurement” (7). The 
reproducibility precision is “condition of measurement, that includes different 
locations, operators, measuring systems, and replicate measurements on the same or 
similar objects” (7). 
1.2 Guide to Expression of Uncertainty in Measurement  
Uncertainty of measurement is defined as “a non-negative parameter characterizing the 
dispersion of the quantity values being attributed to a measurand, based on the 
information used” (7). The Guide to Expression of Uncertainty in Measurement 
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(GUM) provides guidelines for expressing uncertainty in measurement, including 
those for converting the uncertainty estimates into standard form, combining them, and 
calculating the combined uncertainty (1). The aim of GUM is to harmonize the 
different practices for estimating and reporting uncertainty of measurement (29). 
Measurement uncertainty may include components arising from systematic effects, 
and components evaluated by Type A and Type B evaluations of measurement 
uncertainty (1). Both types of evaluation are based on probability distributions, and the 
uncertainty components are quantified by variances (1). Type A evaluation of 
uncertainty is based on statistical analysis of series of observations (1). The type A 
experimental standard deviation characterizes the variability of the observed values or 
their dispersion about their mean (1). Type B standard uncertainty is evaluated by 
scientific judgement based on available information on possible variability, such as 
data provided in certificates, handbooks, manufacturer’s specifications (1). When the 
number of observations is limited, a type B evaluation may be as good as a type A 
evaluation. The distribution of the errors in a Type B uncertainty is claimed to be 
uniform, because sometimes, all that is known are the end-points of the interval 
wherein the quantity varies (30). 
Many guidelines or standards are based on the GUM guidelines (7;18;31;32). A 
bibliography on uncertainty presents several general and specific applications 
documents derived from the GUM over many years (33). According to GUM, the 
evaluation of uncertainty is neither a routine task nor purely mathematical, it depends 
on detailed knowledge of the nature of the measurand and of the measurement (1). 
Therefore, construction of an uncertainty model can be complicated (34).  
An application of a model, based on GUM, for evaluating the uncertainty of a 
measurement result has been demonstrated, in order to harmonize the uncertainty 
evaluation process (35). Data from method validation studies, internal quality control 
and external quality assessment schemes (EQA) are used in the evaluation (35). A 
critique of GUM is that too narrow uncertainty intervals will be presented to the 
clinicians and consequently be misleading, because unexplained outliers that are not 
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unusual in diagnostic assays, due to interfering substances, will not be included in the 
intervals (36).  
1.3 Quality specifications based on biological variation 
Laboratory test results are used for many purposes such as diagnosis, case finding, 
screening, and monitoring (5). Quality specifications should ensure that these clinical 
purposes can be achieved (5). Quality specifications for total allowable analytical error 
can be derived from evaluation of the effect of analytical performance on clinical 
outcome, biological variation, clinician’s opinions, official regulatory bodies, external 
quality assessment and state of the art (37). It is well documented that objective quality 
specifications are necessary in method evaluation and quality control (5). Quality 
specifications for analytical precision and trueness derived from biological variation 
have been set (38). An updated list of analytical quality specifications is available on 
Westgard’s homepage (39).  
According to these specifications, for monitoring a patient’s condition, the analytical 
variation (CVA) has to be below half of the within-subject biological variation (CVI) 
(39). For screening, and diagnosis, when a cut-off point is used, and as related to 
reference intervals, the analytical bias (BA) should be below a quarter of the square 
root of the squared within-subject (CVI) plus the between-subject biological 
variation (CVG) (39): 
CVA ≤ 0.5 × CVI 
BA < 0.25 × (CVI2 + CVG2)1/2                                                                                                
1.4 Treatment of biases 
Systematic and random error cannot be eliminated, but it can often be reduced. GUM 
states that if the systematic effect is significant in size relative to the accuracy of the 
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measurement, a correction can be applied to compensate for the effect, and that “it is 
assumed that the result of a measurement has been corrected for all recognized 
significant systematic effects, and that every effort has been made to identify such 
effects” (1). Although it is recommended to correct for biases, this may not always be 
practical (40). It is proposed, that when there are several sources of uncorrected biases, 
the biases should be added, and the combined bias should be stated together with the 
combined standard uncertainty (40). If these biases are not independent, the degree of 
overlap of the biases should be estimated and subtracted, to avoid doubly counting 
biases (40). According to GUM, measurements results should be corrected for the bias, 
and the uncertainty in the bias correction should be included in the combined standard 
uncertainty. In the proposed approach a complete uncertainty statement should include 
the combined standard uncertainty (biases are corrected), a statement of the bias value, 
and an expanded uncertainty including the effect of the bias (40). 
1.5 Traceability, trueness, accuracy 
Traceability, trueness and accuracy are related terms used in analytical measurements. 
These terms may also be used in the preanalytical field. A metrological traceability 
chain is defined as “sequence of measurement standards and calibrations that is used to 
relate a measurement result to a reference” (7). The trueness is defined as “closeness 
of agreement between the average of an infinite number of replicate measured quantity 
values and a reference quantity value” (7),  while accuracy is defined as “closeness of 
agreement between a measured quantity value and a true quantity value of a 
measurand” (7).  
Establishing metrological traceability satisfies the basic requirements of evidence-
based laboratory medicine (41). The manufacturers have to document the metrological 
traceability for commercially available methods (41). The methods should preferably 
be traceable to a primary reference material or a reference method, and the goal is to 
assure that test results are accurate and comparable over time (41). Specifically, 
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because of a standardization program for glycohemoglobin, harmonization of test 
results between methods and improved analytical precision have become possible (42).  
Shifts in bias or changes in trueness will influence on the number of patients classified 
having a disease according to established decision thresholds, and thereby affect both 
medical outcome and healthcare costs (9). Allowing a bias on e.g. ± 1% for 
cholesterol, will cause approximately ± 6% change in the number of patients passing 
decisions thresholds (9). There are analytical performance standards for individual 
analytes such as the CLIA criteria (43), which involve quality standards for all 
laboratory testing to ensure the accuracy, reliability and timeliness of patient test 
results, regardless of where the test is performed. In EQA, the accuracy of a 
laboratory’s analysing method is determined by comparing the test result for each 
analyte with a target value defined by e.g. the mean of the participants’ responses, or 
value established by reference method. The acceptance limits for quantitative tests in 
EQA are related to the analytical variance. The limits are set to ensure that the test 
results are clinically useful, and that the performance compared with other laboratories 
is acceptable. A high between-laboratory variability may cause wider acceptance 
limits in EQA than what is clinically desirable (44). In order to allow 95% of 
laboratories to meet an EQA challenge, a consensus on minimum level of analytical 
performance has been set by Spanish scientific societies organizing EQA (45).  
1.6 Statistical methods 
There are two approaches to the estimation of uncertainty, the “bottom-up” and the 
“top-down” (18). The “bottom-up” approach quantifies the sources of uncertainty 
individually, and then uses a model to combine them. In contrast, the empirical or 
“top-down” approach involves some level of replication of the whole measurement 
procedure to give a direct estimate of the uncertainty (18). The “top-down” approach 
can be used to estimate the uncertainty from one or more effects, or classes of effects 
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(18). The bottom-up procedure may be useful during method development, and the 
top-down approach for method verification (2). 
By definition, an uncertainty budget is a “statement of a measurement uncertainty, of 
the components of that measurement uncertainty, and of their calculation and 
combination” (7). In study I (Paper I), an uncertainty budget was modelled by 
summing up the expected individual biases and variances in paired data, between 
current practice and the standard method for each uncertainty source, considering the 
distribution of the alternative methods. The modelling in study I is a “bottom-up” 
approach. Doing modelling is about making proper simplifications and assumptions, 
and the assumptions must be validated (34). Study II and III (Paper II and III) are “top-
down” approaches, where linear mixed-effects models were used to identify different 
sources of variation. Mixed-effects models allow the use of clustered multilevel data, 
and separate estimates of fixed and random effects (46). By collecting blood into 
several tubes from both arms from several individuals, and analysing the specimens in 
duplicate, the data set reflected four sources of variability: The between-subject, the 
between-venipuncture, the between-tube defined as the preanalytical variation, and the 
measurement repeatability. Duplicate analyses of control samples are a recommended 
method for estimating analytical precision (47).  
Another choice of statistical method is Empirical Bayesian models that could be used 
as an alternative statistical method to linear mixed-effects models (46). On the 
contrary, analysis of variance is not adapted to data with cluster structure, and 
multivariate analysis of variance is built on analysis where several analytes are 
dependent variables in the same analysis, and consequently based on additional 
assumptions that not necessarily need to be fulfilled. As to repeated measures analysis 
of variance, it is an older method for clustered data, having weaknesses that linear 
mixed-effects models do not have. Linear mixed-effects models do e.g. not demand 
balanced data, and build on fewer assumptions (48).  
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1.7 Preanalytical variables 
1.7.1 Sample collection 
Tourniquets should not be used at higher pressures than 40 mmHg (6), and not longer 
than one minute (11). Long tourniquet application time may result in increase of the 
concentration of macromolecules, blood cells and compounds bound to proteins, while 
the concentration of low molecular analytes are less influenced, because fluid and low 
molecular compounds are moving from the vein into the interstitium (11). Repeated 
clenching and unclenching of the fist should be avoided.  
Needles and winged blood collection sets are color-coded according to the size of the 
inside diameter of the needle (6). The 23-gauge baby-blue butterfly needle indicates a 
smaller diameter than the 21-gauge straight green needle. Collecting blood by using 
the green straight needles is considered gold standard in this work, and is the most sold 
needle (personal communication) according to the Norwegian manufacturer PULS. 
The long flexible tube of the butterfly needle has a dead volume of about 0.5 mL. Of 
the needles used at the pediatric clinic at Haukeland University hospital 50-60% are 
blue butterfly needles. At the outpatient clinic at the main hospital laboratory about 20-
30% is butterfly needles, equally distributed on blue and green butterfly needles. A 
study found no bias when comparing butterfly needles having different gauge for 
analytes such as calcium, CK, LD and potassium (20). When straight needles were 
compared with butterfly needles (both 21-gauge needles), there were found no 
significant differences in the results for several analytes including ALP, calcium, CK, 
LD, and potassium (49). 
By venipuncturing both arms in study II and III, the between-venipuncture variation 
could be estimated, in addition to the fixed effects representing any systematic 
differences between arms, and between types of needles. The tubes should be 
completely filled, and immediately mixed gently by 5-6 inversions to disperse the clot 
activator. Vigorous mixing should be avoided. A study on Li-heparin gel tubes showed 
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a small significant increase of LD and H-index in samples subjected to instant mixing 
directly after the phlebotomy compared to samples without mixing (21). 
1.7.2 Sample handling  
To ensure test reliability, well-trained personnel using appropriate devices is needed 
when collecting blood (50). Gel tubes are widely used to separate serum from clotted 
whole blood. The gel has a controlled viscosity and a specific gravity which make the 
gel move between the serum and the clot during the centrifugation. To avoid 
interference from the gel it is important to follow the manufacturer’s recommendation 
for temperature while storing the tubes, and using the recommended centrifugal force. 
Blood collection tubes should be validated in order to give accurate and precise test 
results (15). The draw should be within 10% of the stated draw, and the amount of 
additive should be within the range specified by the manufacturer (14). 
The pre-centrifugation phase is the time interval between specimen collection, and 
centrifugation (13), called the clotting time in our studies. Complete clotting normally 
occurs within 30 to 60 minutes at room temperature (13). Gel tubes with thrombin 
such as the rapid serum tubes (RSTs) only need 5 min to form a fibrin clot, while gel 
tubes with silica clot activator such as the serum separation tubes (SSTs), need 30 min. 
For plain tubes of glass without additives, 45-60 min clotting time is recommended. In 
clinical research studies, it is recommended to use the same kind of tube from the same 
manufacturer, in order to reduce the uncertainty (50).  
Modern centrifuges have swing-out rotors, are temperature controlled, and the speed 
of the centrifuge can easily be adjusted either by g-force or speed of rotation. 
Operational verification activities of the centrifuges such as speed control and timer 
are strongly recommended (8). It is recommended to follow the specifications of the 
manufacturers of the tubes regarding centrifugation speed and time.  
To prevent disturbance during the clot formation, the tubes should be kept in a vertical, 
closure-up position (13). Blood attached to the tube closure may result in hemolysis in 
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the serum. Serum should be separated from the erythrocytes as soon as possible (13), 
but studies have shown that many analytes were unaffected by cells contact time for 24 
to 72 hours at room temperature (13;51;52). However, the concentration of glucose 
decreased, and LD and potassium increased after 24 hours contact with the clot (52). 
Magnesium is shown to increase 11% after 24 hour delay of centrifugation (53). For 
glucose, LD and potassium it is stated up to two hours stability for uncentrifuged 
specimens (13). Glycolysis is the conversion of glucose or other hexoses into lactate or 
pyruvate (54). Glycolysis decreases serum glucose by approximately 5 to 7% in 1 hour 
in normal uncentrifuged coagulated blood at room temperature (54).  
Temperature and time of storage may influence the stability of biochemical 
components in serum. The serum should be stored at 2–8°C when not analyzed within 
8 hours after the phlebotomy (13). Serum can be stored on gel for up to 48 hours at     
4 oC for most analytes with the exception of some drugs (13). In non-hemolyzed 
serum, separated from the erythrocytes, the glucose concentration is stable for 8 hours 
at room temperature (54). Manufacturers should be requested for stability data since 
different analysing methods may have different stability requirements for the same 
measurand (13).  
1.7.3 Pneumatic tube transport  
Benefits of pneumatic tube systems are improved efficiency and productivity. Several 
researchers have studied the effects of transporting blood samples by pneumatic tube 
systems (22;55-60). Shaking and gravity forces may influence the specimens, e.g. by 
hemolysis, and thereby change the concentration of some analytes (22;55-59). A 
positive relationship is shown between the speed of the pneumatic tube system, and 
increased changes in concentration of potassium and LD (22). Transporting unclotted 
blood and clotted blood have been shown to give the same effect on LD, but 
transporting incompletely filled tubes increases the effect on LD further (59).  
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1.7.4 Hemolysis 
Hemolysis is release of hemoglobin and other intracellular components from 
erythrocytes into plasma/serum (11). Hemolysis may be classified as in vivo and in 
vitro hemolysis. In vivo hemolysis may result from intravascular erythrocyte 
destruction (13), while in vitro hemolysis from the phlebotomy and sample handling 
before analysis. Fragile veins, collection of blood from a hematoma site, prolonged 
tourniquet time, equipment that may lead to turbulent blood path such as butterfly 
needles, and vigorous mixing are examples on blood collection that may result in in 
vitro hemolysis (61).  
The effects of hemolysis are 1) increased intracellular constituents such as LD in 
serum, 2) optical interference, and 3) interference with the reaction mechanism of the 
assay (11). Interference may occur even by low concentration of hemoglobin (11). The 
concentration of potassium in erythrocytes vs normal plasma is 23:1, and for LD 
160:1, respectively (62). Hemolysis is shown to be the leading cause of unsuitable 
specimens in clinical laboratories (61), and may be a suitable indicator for 
preanalytical quality (63).  
1.7.5 Literature search 
The general literature search was completed at the end of February 2013. Search 
criterias in Pubmed (My NCBI what's new results from the National Center for 
Biotechnology Information at the U.S. National Library of Medicine) were “clinical 
chemistry uncertainty”, “preanalytical phase”, “preanalytical”, “blood tubes 
phlebotomy”, “uncertainty budget”, “stability clinical chemistry analytes storage”, 
“clinical chemistry quality specifications”, and “metrological traceability”.  
A specified literature search for using linear mixed-effects models in estimating 
uncertainty in clinical chemistry was performed 18.12.2012. Only one study (64), from 
the search in Web of Science, had some similarity to our studies II and III, concerning 
the approach, design, method, subject area and research in question.  
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Detailed description of the literature search 18.12.2012: 
Search in Pubmed: Search queries as “Laboratories, Hospital” [Mesh] OR (Blood 
Specimen Collection OR Phlebotomy OR preanalytical) gave 21298 matches, while 
the search query (linear mixed effect model) gave 1527 matches. The combination 
gave 7 matches. Paper II was not among the 7. None of matches showed similarity to 
study II and III.  
Search in EMBASE: The search query (“linear mixed effect* model*”) gave 1618 
matches. Search queries (analytical error) OR (blood analysis) OR (blood sampling) 
OR (preanalytical) OR (laboratories) OR (laboratory) gave 349881 matches. The 
combination gave 132 matches, where one of them was Paper II. Evaluated from the 
titles and the abstracts, the other 131 matches were not of current interest.  
Search in Web of Science: The search query (“linear mixed effect*model*”) gave 1468 
matches. Search queries as (laborator*) OR (preanalytical) OR (“blood specimen”) OR 
(phlebotomy) OR (“blood analys*”) OR (“blood sampling”) OR (“analytical error”) 
gave 503155 matches. The combination gave 41 matches, where one of them was 
Paper II. Based on evaluating the titles and the abstracts, only one of the papers may 
be of current interest (64), as mentioned above. The researchers examined the effect of 
time, tube, anticoagulant type, on serum and plasma profiles within low-molecular-
weight proteome (64). Blood was collected into several tubes from 3-6 individuals in 
each project, and the tubes were processed differently further on. Cluster analysis was 
used to identify samples with similar peak profiles. Mean intensities of the different 
groups were estimated and compared to a basis point. Compared with our studies II 
and III, neither random effects nor confidence intervals were estimated. 
Search in MathSciNet: The search query “linear mixed effects model*” gave102 hits.  
The papers were within mathematical statistics.  
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Search in Jstor Statistics: The search query ((“linear mixed effects model*”)) AND 
(laborator* OR preanalytical OR blood) gave 150 hits. Among these 150 matches we 
were not able to find any appropriate paper with preanalytical or laboratory focus. 
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2. AIMS  
The overall aim of this thesis was to establish a modelling framework for estimating 
preanalytical uncertainty in clinical chemistry analyses. The specific aims were:  
Paper I 
For each uncertainty source, summing up the expected biases and variances in paired 
data between a standard method for handling blood samples and alternative methods 
used in current practice, and considering the distribution of alternative methods, 
develop an uncertainty budget for preanalytical variables in clinical chemistry 
analyses. The uncertainty budgets should include the uncertainty added to test results 
by using different kinds of blood tubes and instruments, prolonged clotting time and 
centrifugal force, and delays in measurement.  
Paper II 
By linear mixed effects-models, detect any difference in preanalytical variation when 
blood is collected into two different types of tubes, and estimate the between-
venipuncture variation, and the preanalytical variation (excluding the between-
venipuncture variation), and the measurement repeatability, together with any fixed 
effects, when the phlebotomy and the sample handling are performed optimally for 15 
clinical chemistry analytes.  
Paper III 
By linear mixed-effects models determine whether specific, preanalytical treatments 
increase preanalytical variation and bias test results compared with optimal treatment 
for 21 clinical chemistry analytes. The following treatments are examined: 
Transporting blood samples in a pneumatic tube system vs manual delivery, collecting 
blood using 23-gauge butterfly needles vs 21-gauge straight green needles, and mixing 
blood samples by only one inversion vs five inversions. 
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3. MATERIALS AND METHODS 
Table 1 presents the preanalytical variables examined, the participants included, the 
data structure, statistics and outcome in Paper I, II and III. 
 
Table 1. Preanalytical variables examined, participants included, data structure, 
statistics and outcome in Paper I, II and III. 
Paper Preanalytical 
variables  
Participants Data structure Statistics Outcome 
I Blood tubes Hospitalized 
patients              
n=33 + 34 
Paired observationsa 
Discrete distribution 
Own modelb Bias (SDc) 
 Clotting time Hospitalized 
patients              
n=45 
Paired observations 
Continuous distribution  
Own model Bias (SD) 
 Centrifugal force Hospitalized 
patients          
n=28 
Paired observations  
Continuous distribution  
Own model Bias (SD) 
 Storage time Hospitalized 
patients              
n=31 
Paired observations 
Continuous distribution  
Own model Bias (SD) 
 Instruments Serum from 
the routine         
n=500 
Paired observations 
Discrete distribution  
Own model Bias (SD) 
II Optimal treatment Volunteers         
n=20 
Hierarchical cluster data Linear mixed-
effects models 
Bias (95% CI)   
SD (95% CI) 
III Ways of 
transportation  
(experiment 1) 
Outpatient 
clinic  n=30 
Hierarchical cluster data Linear mixed-
effects models 
Bias (95% CI)   
SD (95% CI) 
 Needles and   
mixing methods 
(experiment 2) 
Outpatient 
clinic n=30 
Hierarchical cluster data Linear mixed-
effects models 
Bias (95% CI)   
SD (95% CI) 
a Paired observations between the alternative method and the standard method.                                                       
b An uncertainty budget is modelled by combining expected biases and variances between standard method and 
current practice from each uncertainty source.                                                                                                           
c SD of the differences between the paired data.                                               
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3.1 Ethical considerations 
All studies were performed in accordance with the Helsinki declaration. Study II and 
III were approved by the Regional Committee for Medical and Health Research Ethics, 
Western Norway (REC no 022.28). Study I was a quality assurance project, and quality 
assurance and evaluations which is part of the health services, and technical and 
methodological scientific development using anonymously biological materials, is 
exempted from approval by Regional Committee for Medical and Health Research 
Ethics, Western Norway. Written informed consent was obtained from all participants 
in study II and III, while in study I informed oral consent was obtained. In study II and 
III, the test results were assessed by the medical doctor executive of the project. In all 
studies the name, and date of birth was removed, and the samples were analysed 
anonymously. The sample materials were discarded after measuring. The following 
documents are enclosed in the appendices: The approval documents from the Regional 
Committee for Medical and Health Research Ethics (no. 1), the Norwegian Social 
Science Data Services (no. 2), the Norwegian Directorate of Health (no. 3), and the 
enquiry and consent declaration for participation (no. 4).  
3.2 Participants and sample collection  
In study I, the single blood tube needed from each patient was collected from 
consenting hospitalized patients in the course of routine blood collections for tests 
already ordered by the patients' physicians. The patients were conscious, and able to 
understand the enquiry. Most of the phlebotomies were done by the same medical 
technician. Paper 1 consisted of 5 subprojects. Four of five subprojects involved 
phlebotomy on approximately 30 patients in each, while one involved 500 serum 
samples previously analysed on two different Roche Modular Analytics SWA 
instruments by photometric methods (Roche Diagnostics GmbH) in our department.  
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In study II, blood was collected from 20 non-fasting healthy volunteers employed at 
our laboratory. There were no specified inclusion or exclusion criteria. The mean 
venipuncture duration for both arms was 3 min (range 2 – 7 min). 
In study III, blood was collected from 30 non-fasting, consecutively recruited patients 
at our outpatient clinic, separately for experiment 1 and experiment 2. The sampling 
was stratified as approximately equal number of out-patient men and women above 18 
years of age. The mean venipuncture duration for both arms was 3.5 min (range 2.5 – 
6 min). To limit the amount of blood collected, patients with only a few routinely 
ordered tests were chosen. In study II and III the same medical technician performed 
all phlebotomies with the participant remaining in a sitting position for approximately 
10 min at ambient temperature between 9 AM – 1 PM. The tourniquet was loosely 
fastened and released after < 1 minute, as soon as blood appeared. Repeated clenching 
and unclenching of the fist was not allowed. Table 2 shows the different blood tubes 
used in the studies. 
 
Table 2. Vacutainer blood tubes (Becton Dickinson, USA) used in the studies. 
Paper Type of blood tube Tube material Additives  
I Serum separating tube (SST) Glass Gel + silica clot activator 
 SST II Plus Plastic Gel + silica clot activator 
 Plain Glass None 
II Rapid serum tube (RST) Plastic Gel + thrombin-based medical clotting agent 
 SST II Advance  Plastic Gel + silica clot activator 
III SST II Advance Plastic Gel+ silica clot activator 
 
Power analysis can be used to calculate the sample sizes necessary to detect a specified 
difference when the error variance is known (or can be guessed at) (65). We did not 
perform power calculations in any of our studies. In study I we did not have a priori 
data on the SD of the differences in the paired data between the standard method and 
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the alternative method, while in study II it was not possible to do power calculations, 
because we did not have a priori SDs for the between-individual SDs, the between-
venipuncture SDs, the preanalytical SDs (excluding the between-venipuncture SD) or 
the measurement repeatability SDs. 
In study III, the sample size was increased from n=20 to n=30, because of a more 
heterogeneous population than in study II. We did not have a priori SDs for the new 
treatments and levels in study III, such as the between-venipuncture SDs when using 
both butterfly and green needles, preanalytical SDs (excluding the between-
venipuncture SD) for suboptimally treated samples, or measurement repeatability SDs 
for duplicates from test results from patients. 
3.3 Analytical methods  
Laboratory of Clinical Biochemistry (LKB) produced about 6.2 million test results in 
2012. The analytes examined in study I, II and III were among the most generally 
ordered at our laboratory (Figure 1). In study I four analytes were examined, in study 
II 15 analytes, and in study III 21 analytes (specified in Table 4). The analyses should 
not be too expensive, since the studies involved many specimens and duplicates 
analysis. The clinical chemistry measurements were performed at Roche Modular 
Analytics SWA (serum work area) on P800 module instruments by photometric 
methods from Roche Diagnostics GmbH. The photometric methods are detailed in the 
papers. The electrolytes were measured with ISE (ion-selective electrode) indirect 
method, while folate was measured with the Elecsys competitive method Folate III on 
E170 modules (Roche Diagnostics GmbH). The hemolysis was measured by a 
photometric method as the hemoglobin index (H-index), where 100 H-index units 
correspond to a hemoglobin concentration of about 0.06 mmol/L (0.1 g/dL). The 
analysing methods have good analytical precision and trueness. The specimens were 
analysed anonymously and randomly in duplicates within the same analytical run to 
ensure the same measuring conditions. 
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At LKB, the standard procedure is to reject test results for LD and folate when the H-
index is above 50, and for potassium when the H-index is above 65.  
 
 
 
Figure 1. The figure shows the analytes examined, and the number of analyses 
performed at LKB in 2012. 
3.4 Paper I 
3.4.1 Specimen handling  
For each uncertainty source, we specified a standard (recommended) method of 
preanalytical treatment and alternative methods of treatment, which were within 
clinical practice (Figure 2). Each of the 5 uncertainty sources (a–e) was studied 
separately by paired observations between the alternative methods and the standard 
method. The alternative methods are used to a variable extent in current practice. 
a) Different blood tubes: One SST tube (standard method) and one plain tube 
(alternative method) were collected from each patient (N=33), and one SST 
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(standard method) and one SST II Plus tube (alternative method) were collected 
from each patient (N=34). All pairs of tubes had equal clotting time (between 45 
and 120 min) and were centrifuged at 1300g, except the SST II Plus tubes that 
were centrifuged at 1850g as recommended. 
b) Clotting time: Two SSTs were collected from each patient (N = 45). One of the 
paired SSTs was centrifuged as recommended after 40–70 min clotting time 
(standard method), and the other after 120–150 min (alternative method).  
c) Centrifugal force: Two SSTs were collected from each patient (N = 28). One of 
the paired SSTs was centrifuged at 1300g (standard method) and the other at 
2350g (alternative method) after equal clotting time (between 45 and 70 min).  
d) Storage time: Two SSTs were collected from each patient (N = 31). All pairs of 
tubes had equal clotting time (between 45 and 120 min), and were centrifuged at 
1300g. From one of the paired SST tubes, 500 μL serum was frozen at               
–80°C within 4 h (standard method). The other of the paired tubes was left at 
room temperature for 48 hours, then 500 μL serum from this tube was frozen at 
–80°C (alternative method).  
e) Different instruments: Aliquots of serum samples from the routine (~ 500) were 
analyzed, one per day, at equal time points on both Modular I (standard method) 
and Modular II (alternative method).  
 
Figure 2 presents the description of the standard method, the alternative methods 
where the maximum deviations for the continuous uncertainty sources are shown, and 
the modelled current practice. The probability distributions were compatible with 
actual use in our laboratory. 
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Figure 2. The description of the standard method, the alternative methods, and the 
modelled current practice (Paper I).  
 
3.4.2 Statistics: Uncertainty budget  
Figure 3 shows the design of study I. The mean and variances of differences were 
calculated between paired observations from comparing a standard method with an 
alternative method. When comparing the results from the standard method with an 
alternative method, the results from one of the methods can show a permanent 
tendency to deviate from the other. We call this systematic effect a bias, and it was 
estimated as mean of differences. The confidence interval (CI) for the mean of 
differences could be expected to be much narrower than the CI for the mean values for 
each data set, because the between-individual variation is not included. It is realistic to 
presume approximately normal distribution of the differences. Because we were 
The standard method 
 a) Use of SST tubes 
 b) Clotting time 45 min
 c) Centrifugal force 1300g
 d) Serum analysed fresh 
 e) Instrument: Roche Modular I
The alternative methods 
 a) Use of SST II Plus or Plain tubes 
 b) Clotting time two hours
 c) Centrifugal force 2350g
 d) 48 hours storage of serum
 e) Instrument: Roche Modular II  
The current practice is modelled as
 -  Probability for use of different tubes:
    SST p=0.8, SST II Plus p=0.1, Plain p=0.1
 -  Analysis on Modular I and Modular II p=0.5
 -  Clotting time, centrifugal force and storage    
     time rectangularly distributed 
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interested in the variance due to preanalytical treatment, the variance of differences 
actually measured, was adjusted for analytical variation (66).  
We modelled discrete and continuous uncertainty sources separately (Figure 3). If the 
set of all possible values of a random variable is a countable set, then it is called a 
discrete random variable (67). For the discrete uncertainty sources, such as using 
different types of tubes, a number of alternative treatments were defined, together with 
their probabilities in current practice (Figure 2). The distribution should be estimated 
from frequency data on the use of each treatment within the laboratory. With 
increasing probability for use of the standard treatment, the bias and variance will 
decrease. With increasing probability for use of the alternative treatments, the bias and 
variance will increase (until a definite limit).  
A random variable is called a continuous random variable if it is assumed capable of 
attaining any value in some interval, and not just discrete points (67). For the 
continuous source, such as clotting time, we assumed that the treatments in current 
practice constituted a continuum with the standard treatment at one end, and a 
maximally distant alternative treatment at the other end. It was assumed that the actual 
treatment is rectangularly distributed, because the uncertainty variable is within a 
restricted interval. The rectangular or so-called uniform probability density is zero 
outside the particular interval, and within the interval, the probability density is a 
positive constant (30). It was assumed linearity of means and SDs for the continuous 
source of uncertainty. These assumptions have not been empirically justified. 
For each source the expectation and standard deviation of the differences based on the 
paired data were estimated. The formulas for double expectation and double variance 
were used to estimate the expectations and variances of the differences for each 
uncertainty source, assuming that the uncertainty sources varied randomly according 
to a known distribution (67). It was assumed that the differences are independent of 
each other, and that each of these differences has the same distribution as if the actual 
uncertainty source is compared with a fully standardized situation. Under these 
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conditions, the expected difference D (combined bias) is equal to the sum of the 
expected individual differences for each uncertainty source: 
ED = ED1 + ED2 + ED3 + … + EDk        
Under the same conditions, the variance of the combined differences is equal to the 
sum of the expected individual variances: 
Var(D) = Var(D1) + Var(D2) + Var(D3) + … + Var(Dk)   
 
In order to alleviate the burden of computations, Microsoft Excel sheets were prepared 
and published online as “Supplemental Data – Uncertainty calculations” to Paper I. An 
example of the calculations sheets is included together with Paper I. An appendix, 
containing assumptions and modelling details, was published as “Supplemental Data – 
Appendix” to Paper I. The appendix is included together with Paper I.                       
The biases and SDs estimated in study I do not refer to the same biases and SDs as in 
study II and III. 
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Figure 3. The design of study I.  
 
3.4.3 Methodological considerations 
When comparing the results from the standard method with an alternative method, the 
estimates of the mean and the SD of differences are meaningful only if we can assume 
that the bias and variation is uniform for the whole concentration range of the test 
results. The usual deviation from this assumption is an increase or decrease in the 
variability of the differences (plotted along the y-axis) with increasing concentration at 
the x-axis (66), where the mean of the test results from both methods are plotted. The 
assumptions were checked graphically by evaluating the Bland Altman plots, and were 
evaluated to be acceptable. 
We assumed that a rectangular distribution fitted the continuous uncertainty source. A 
triangular distribution may also be suitable as a continuous distribution for the clotting 
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time, centrifugal force or storage time, but since we did not have any specific 
information about the distribution, we chose the rectangular distribution.                      
A simplifying approximation included linearity of the means and SDs for continuous 
sources of uncertainty. Specifically, they are linear functions of the treatment actually 
used with slopes α and β, respectively, as detailed in Paper 1. 
Current practice for the categorically distributed uncertainty sources was modelled in 
accordance with our practice. This demands that the probabilities of using the different 
kind of tubes have to be known and constant, and that one tube is defined as the “gold 
standard” tube. The bias between methods at two instruments was included in the 
uncertainty budget. However, a stable bias between the instruments was not verified.  
3.5 Paper II and III 
3.5.1 Specimen handling 
In study II, the phlebotomy and the sample handling were performed optimally 
according to existing standards (6;13). In order to estimate the uncertainty caused by 
the phlebotomy, venipunctures were performed on both arms of each participant by 
using 21-gauge straight green needles. Two SST and two RST tubes were collected in 
random order from each arm, for a total of 8 tubes from each person. The tubes were 
completely filled, mixed gently by 5 inversions, and put in a vertical position. Table 3 
presents the optimal practice for study II, the optimal and alternative practice in study 
III, and the model estimates in study II and III.  
In study III, experiment 1, four SST gel tubes were collected from each arm by using 
21-gauge straight green needles. Two SST tubes, randomly chosen from each arm, i.e. 
a total of 4 tubes from each patient, were transported after 10 min clotting time by the 
pneumatic tube system (TranspoNet Pneumatic Tube Systems, Swisslog, Switzerland) 
installed between the intensive care unit and LKB. Blood samples were padded in 
bubble plastic before transportation, to avoid the samples to toss around inside the 
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cartridge. The other 4 gel tubes were manually delivered to the laboratory. The 
average duration of both pneumatic and hand delivery transport was approximately 2.5 
min.  
In study III, experiment 2, four SST tubes were collected from one arm using a 21-
gauge straight green needle, and four SST tubes from the other arm using a 23-gauge 
butterfly needle (Figure 4). Two SST tubes, randomly chosen from each arm, i.e. a 
total of 4 tubes from each patient, were optimally mixed by gently inverting the tubes 
5 - 6 times immediately after the phlebotomy. The other 4 gel tubes were mixed by 
only one inversion.  
In experiment 1 and 2, the clotting time was 30 min, the tubes were centrifuged for 10 
min at 1600 g, and the specimens were analysed in duplicates within 4 hours after the 
phlebotomy. 
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Table 3. The design and model estimates in Paper II and III. 
Paper II Optimal practice Estimated SDs  Estimated biases  
 RST tubes                   
5 min clotting time 
Centrifugal force 
1600 g 
Analysed on average 
33 min (range 21-62 
min) after phlebotomy  
SST II Advance tubes       
30 min clotting time 
Centrifugal force    
1600 g 
Analysed on average  
61 min (range 46-95 
min) after phlebotomy  
Between-venipuncturea  
Preanalytical (excluding the 
between-venipuncture)b 
Measurement repeatabilitya  
RST vs SST 
Left arm vs right arm 
Paper III Alternative practice Optimal practice Estimated SDs  Estimated biases 
Experiment 
1 
Manual delivery Pneumatic tube 
 
Between-venipuncturea  
 
Preanalytical (excluding the 
between-venipuncture)b  
Measurement repeatabilitya  
Pneumatic vs                
manual delivery 
Experiment 
2 
Green needles Butterfly needles Between-venipuncturea  
 
Preanalytical (excluding the 
between-venipuncture)b 
Measurement repeatabilitya  
Butterfly vs            
green needles 
Optimal mixing Suboptimal mixing Suboptimal vs          
optimal mixing 
a Estimated using the whole data set.                                                                                                                          
b Estimated separately for alternative practice and optimal practice, and for the whole data set.     
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Figure 4. In study III, experiment 2, blood was collected into 4 SST tubes from each 
arm, by using green straight needle in one arm, and butterfly needle in the other. The 
blood was mixed differently, and the specimens were analysed in duplicates.   
 
3.5.2 Statistics: Linear mixed effects models  
The data in study II and III were analyzed by use of linear mixed-effects models (46). 
The statistical calculations were done in R (The R Foundation for Statistical 
Computing, Wien, Austria) with the package nmle (Linear and Nonlinear Mixed 
Effects Models) (68). The level for statistical significance was set to 0.05, and 95% 
CIs for both the fixed and random effects were calculated. Comparisons of the SDs for 
random effects were performed by evaluation of the overlap of their CIs, and the SDs 
were considered significantly different when their CIs did not overlap. Mixed-effects 
Green needle Butterflyneedle
Patient
SST tube SST tube SST tube SST tube SST tube SST tube SST tube SST tube
Optimal
mixed
Suboptimal
mixed
Suboptimal
mixed
Optimal
mixed
Right arm Left arm
Suboptimal
mixed
Suboptimal
mixed
Optimal
mixed
Optimal
mixed
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models allow analyses of multi-level data, and thereby allow separate estimates of 
fixed and random effects. Multi-level data can be achieved by collecting and analyzing 
the blood samples from several individuals (individual level), performing two 
venipunctures on each individual (venipuncturing level), collecting several tubes from 
each venipuncture (tube level), and by analyzing each blood tube in duplicate 
(measurement level). 
In study II and III, random effects are expressed as standard deviations for variation 
between groups at each level, e.g. between individuals (the between-individual 
biological variation), between arms (the between-venipuncture variation), between 
tubes from each arm (the preanalytical variation), and duplicates of each tube 
(measurement repeatability). The random variations are assumed to be independent of 
each other. The between-individual SDs were not presented in the papers, because the 
estimates were not relevant in our research. Only by also estimating the measurement 
repeatability the preanalytical variation will be correctly estimated, and the 
preanalytical and analytical variation could be compared to each other. Restricted 
maximum likelihood is the most common technical method used in linear mixed-
effects models to estimate the standard deviations.  
Figure 5 presents the design of study II. The minimal inevitable preanalytical 
uncertainty will influence all test results, and may be compared with intra-individual 
biological variation and analytical variation. The collection of blood into both RST 
and SST tubes enabled us to detect any differences in preanalytical SDs and fixed 
effects, between the two clusters of data. 
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Figure 5. The design of the model in Paper II.  
 
In study III, the preanalytical SDs (excluding the between venipuncture SDs) were 
estimated separately for each of the paired treatments. The paired treatments involved 
samples that were suboptimally treated compared with optimally treated: 
x  transportation in pneumatic tube vs with manual delivery (experiment 1)  
x  collecting blood using butterfly needles vs green needles (experiment 2) 
x  mixing blood tubes by only one inversion vs optimally mixed (experiment 2) 
 
We hypothesized that the suboptimal treatment causes a higher preanalytical SD and a 
bias in test results compared with the optimally treated samples. Biases are connected 
Random and fixed effects
SDs:
• Between persons
• Between arms (venipuncture)
• Between tubes (preanalytical)
• Between duplicates (analytical)
Mean differences (biases):
• SST versus RST tubes
• Right versus left arm
Optimal phlebotomy
and preanalytical treatment
Linear mixed effects models
BiasesSDs
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to explanatory variables and not to the levels, e.g. type of tubes or needles, or different 
transportation.  
A statistical model for the empirical estimation of uncertainty (18) can be compared 
with our studies: 
s2total = s2between-target + s2sampling + s2analytical 
The between-target SD represents the variation between targets, and may be compared 
with the between-venipuncture SD. The sampling SD is the between-sample SD on 
one target, and may be compared with the between-tube or preanalytical SD 
(excluding between-venipuncuture SD). The analytical SD is the between-analysis 
variation on one sample, and may be compared with the measurement repeatability 
SD.  
3.5.3 Methodological considerations 
The widths of the CIs  
Occasionally, in linear mixed-effects models, the estimation of random effects results 
in very wide 95% CI, indicating that the model is unstable. The non-convergent or 
extremely wide intervals for some analytes presumably result from a model that is too 
large for the size of the data set, given the actual variation in the analytes in question. 
The random structure of the model should be simplified when the estimates are close 
to zero, by respecifying the model to include fewer random effects (68).  
The higher number of participants, the narrower the width of the CIs will be both for 
the fixed and random effects, but the variability of the test results will also influence 
the width of the CIs. The CIs of the between-venipuncture SDs are pretty wide, 
compared with the CIs of preanalytical SDs and the measurement repeatability in 
study II (Figure 6).  
47 
 
Skewed data  
Both in experiment 1 and 2 in study III, the distributions of test results were 
particularly positively skewed for some of the analytes, generally with high test results 
from only one patient out in the right tail. Test results from blood collections on 
healthy volunteers in study II, did not have any high values in the tail, and 
consequently the test results were less skewed than the test results from blood 
collected on patients in the out-patient clinic in study III.  
In study III, the distributions of the test results in the underlying population were 
evaluated. The number of test results from the patient data system varied between 
several hundred to thousands for the different analytes. The test results from the 
patient data system had more or less skewed distributions, and the test results in the 
selected samples of patients in experiment 1 and experiment 2, would probably follow 
the same distribution. The test results for the skewed analytes in study III were then 
log transformed, in order to get them more normally distributed, but the log 
transformation caused overcompensation for some analytes, giving a left tailed instead 
of a right tailed skewed distribution. To recalculate the log transformed estimates of 
random and fixed effects back to ordinary data is difficult, and because also the log 
transformed estimates are difficult to interpret, we chose not to use log transformed 
data. The main analysis was performed using all the data, but sensitivity analysis was 
done by excluding the high test results far out in the right tail of the distribution. 
Generally, the high results should not be removed from the main analysis, because 
they are part of the variables’ natural variation.  
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3.6 Combining bias and uncertainty, a follow-up study 
3.6.1 Mean square error budget  
Mean squared error (MSE) is defined as the expected mean squared deviation from a 
reference value, or a true value, and covers both the bias and the variance of the 
differences (67). The combined bias and SD from the uncertainty budget (Paper I) are 
combined to a mean square error defined as:                                                                        
MSE = bias2  +  SD2                                                                                                     
Root mean square error (RMSE) is defined as √MSE.                                                                      
The preanalytical uncertainty interval can then be calculated as:  
Measured value ± 2· RMSE                                                                                             
RMSE has the same units as the quantity being estimated.  
The MSE budget is presented under Results, and was not presented in Paper I. 
3.6.2 Recalculation of bias to random variation 
The fixed effects estimated in Paper II and III may be a basis for the calculation of 
random variation, by connecting the fixed effects to assumptions which can be 
empirically stated, built on data about clinical practice, or some “what if” assumptions 
totally or partly built on clinical opinion. An example on how a bias can be 
recalculated to random variation is presented under Results. The recalculated random 
variation can be compared with the random effects estimated directly in the model. 
These calculations have not been presented in any of our papers, and is planned to be 
the subject of further work. 
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4. RESULTS 
Table 4 presents an overview of the results separately for Paper I, II and III, and the 
analytes examined in each study.  
Table 4. An overview of the results separately for Paper I, II and III, including the 
analytes examined. 
Analytes Results Paper I 
Glucose                   
Calcium              
Magnesium           
Creatinine 
The combined expected biases (SD) in the preanalytical uncertainty budgets:  
Calcium: –0.011 (0.0182) mmol/L  
Creatinine: 0.5 (1.81) μmol/L 
Glucose: –0.15 (0.130) mmol/La 
Magnesium: 0.006 (0.026) mmol/L  
                                                                                                                                                        
The uncertainty sources contributing to the uncertainty budgets were using different blood 
tubes and instruments, prolonged clotting time, centrifugal force, and storage time. 
 Results Paper II 
Albumin, ALP, ALT, 
Calcium, Cholesterol,     
CK, Creatinine, GGT, 
Glucose, HDL-C,              
H-index, LD,      
Magnesium, Potassium, 
Sodium, Triglycerides  
Fixed effects                                                                                                                             
Statistical significant mean differences (p<0.05) were seen between SST vs RST tubes for:       
Albumin, calcium, cholesterol, glucosea, H-index, LD, magnesium, and potassium   
Random effects (results from both the SSTs and the RSTs are included)                              
LD: Preanalytical SD (excluding between-venipuncture) was significantly higher than 
measurement repeatability.                                                                                         
Potassium: Preanalytical SD and the between-venipuncture SD were significantly higher 
than the measurement repeatability.                                                                               
Glucose: Between-venipuncture SD was significantly higher than the preanalytical SD and 
the measurement repeatability. 
 Results Paper III 
Albumin, ALP, ALT, 
Bilirubin, Calcium, 
Cholesterol, CK, 
Creatinine, Folate,       
GGT, Glucose, HDL-C,    
H-index, Iron, LD, 
Magnesium, Phosphate, 
Potassium, Sodium,               
Total protein,  
Triglycerides, Uric acid 
Fixed effects                                                                                                                                
Statistical significant mean differences (p<0.05) were seen between:                   
Pneumatic tube transport vs manual delivery for: LD and magnesium 
Using butterfly needles vs green needles for: Calcium, CK and LD 
Suboptimal vs optimal mixing for: Iron 
Random effects                                                                                                                              
CK and glucose: Preanalytical SD (excluding the between-venipuncture SD) for samples          
transported in the pneumatic tube system was significantly higher than the manually 
delivered samples. 
ALP: Preanalytical SD (excluding the between-venipuncture SD) for samples collected using 
butterfly needles was significantly higher than the samples collected by using green needles. 
a Glucose was the only analyte falling outside the quality specifications for analytical bias, when the significant 
biases between different preanalytical treatments in Paper II and III, and the combined biases from the 
uncertainty budget in Paper I, were compared with quality specifications. 
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4.1 Paper I 
4.1.1 Main results 
The expected individual biases and variances, between current practice and the 
standard method for each uncertainty source, were summed up, in order to estimate the 
combined expected bias and variance. The combined expected biases in the 
uncertainty budgets were for calcium  –0.011 mmol/L, creatinine 0.5 μmol/L, glucose 
–0.15 mmol/L and magnesium 0.006 mmol/L (Table 2, Paper I).  
For glucose, the uncertainty budget shows that prolonged clotting time (-0.091 
mmol/L) and storage of serum on gel up to 48 hours at room temperature (-0.058 
mmol/L) gave the greatest contribution to the combined bias (Table 2, Paper I). Using 
different kinds of tubes and instruments, and prolonged centrifugal force gave minor 
contributions. For calcium, prolonged clotting time (-0.010 mmol/L) gave the greatest 
contribution to the combined bias, and for creatinine, the storage of serum on gel up to 
48 hours (1.1 μmol/L). For magnesium it was the mean difference at 0.014 mmol/L 
between the SST II Plus vs SST that gave the greatest contribution from the paired 
data (Table 1, Paper I). But in the uncertainty budget the contribution from using 
different blood tubes was small, because the probability for using the SST II Plus tube 
was modelled to P=0.1, using Plain tubes to P=0.1, and using SST tubes to P=0.8. 
4.2 Paper II and III 
4.2.1 Main results, Paper II 
The uncertainty chain starts with the choice of tube. Statistically significant mean 
differences were seen between SST tubes vs RST tubes for 7 of the 15 analytes (Table 
1, Paper II): Calcium 0.013 mmol/L, glucose -0.16 mmol/L, magnesium 0.005 
mmol/L, and H-index 1.54 (P<0.001), and for albumin 0.16 g/L, cholesterol 0.025 
mmol/L, LD 1.8 U/L and potassium 0.039 mmol/L (P<0.05). There were no 
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significant fixed effects indicating differences between venipunctures in left vs the 
right arm. 
The preanalytical SDs (excluding between-venipuncture) estimated separately for use 
of the SST tubes and RST tubes were not found to be significantly different from each 
other (Table 2, Paper II), therefore, the results from both tubes were included in the 
subsequent calculations of random variation. For glucose, the between-venipuncture 
SD at 0.20 mmol/L, turned out to be the dominant source of variation (Table 3, Paper 
II). For LD and potassium, the preanalytical SDs (excluding between-venipuncture 
SD) were significantly higher than the measurement repeatability SDs (Table 3, Paper 
II). The increase of the total uncertainty is more than 100% for albumin, ALP, CK, 
glucose, LD, and potassium when the preanalytical contribution is added to the 
measurement repeatability variation (Table 5). For ALT, sodium and magnesium, the 
combined CV% is only slightly larger than the measurement repeatability, meaning 
that the preanalytical variation is negligible. The CV% in Table 5 is calculated based 
on the mean of the test results and SD estimates from study II (Table 3, Paper II). The 
CV% can be combined as long as they share a common mean (5). 
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Table 5. The table presents the preanalytical variation including the between-
venipuncture variation, the measurement repeatability, and the preanalytical and 
measurement repeatability combined for each analyte in study II.  
  CV% 
Analytes Mean (Range)a 
 
Preanalytical 
variation including 
between 
venipunctureb 
Measurement 
repeatability 
Preanalytical and 
measurement 
repeatability 
combinedc 
Albumin, g/L 46.1 (41.6 – 50.4) 1.3 0.7 1.5 
ALP, U/L 71.1 (46 – 107) 1.5 0.7 1.7 
ALT, U/L 27.8 (10 – 67) 2.1 4.2 4.6 
Calcium, mmol/L 2.40 (2.20 – 2.53) 0.7 0.6 1.0 
Cholesterol, mmol/L 5.23 (3.57 – 7.65) 1.6 1.0 2.0 
CK, U/L 118.3 (52 – 191) 1.5 0.8 1.7 
Creatinine, μmol/L 70.4 (57 – 92) 1.5 1.0 1.8 
GGT, U/L 26.2 (8 – 160) 1.9 2.3 3.0 
Glucose, mmol/L 5.2 (4.04 – 8.50) 4.0 1.1 4.2 
HDL-C, mmol/L 1.82 (1.03 – 3.07) 1.4 1.0 1.8 
LD, U/L 177.3 (97 – 223) 2.3 1.1 2.5 
Magnesium, mmol/L 0.85 (0.75 – 0.94) 0.7 1.3 1.4 
Potassium, mmol/L 4.38 (3.75 – 4.93) 2.7 0.7 2.8 
Sodium, mmol/L 140.5 (135.5 – 143.8) 0.2 0.5 0.6 
Triglycerides, mmol/L 0.91 (0.49 – 2.18) 2.2 1.5 2.6 
a The mean and the range of observations in study II.                                                                                                    
b The preanalytical variation (excluding the between-venipuncture variation) and the between-venipuncture 
variation combined.                                                                                                                                                     
c The between-venipuncture and the preanalytical (excluding between-venipuncture) variation, and the 
measurement repeatability are combined.                                                                                                                  
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4.2.2 Main results, Paper III 
The mean differences were estimated in the paired treatments between transporting 
samples in a pneumatic tube system vs manual delivery, use of butterfly vs green 
needles, and suboptimal vs optimal mixing (Table 1, Paper III). In experiment 1, 
transporting samples by the pneumatic tube system added a significant bias to the test 
results for LD at 4.5 U/L (P<0.001) and magnesium at 0.0021 mmol/L (P=0.003) 
(Table 1, Paper III). The H-index was not affected. Statistical significant mean 
differences were also seen between using butterfly needles vs green needles for 
calcium and CK, and between suboptimal vs optimal mixing for iron (Table 1, Paper 
III). LD was significantly lower (-1.6 U/L, P=0.047) when using butterfly needles 
compared with using green needles, when samples with H-index > 40 were excluded.  
The preanalytical SDs (excluding the between-venipuncture SD) were estimated 
separately for each of the paired treatments (Table 2, Paper III). For glucose the 
preanalytical SD (0.12 mmol/L, 95% CI 0.097 – 0.14) for samples transported in the 
pneumatic tube system was significantly higher than the preanalytical SD for samples 
manually delivered (0.077 mmol/L, 95% CI 0.062 – 0.095). The preanalytical SDs 
(excluding the between-venipuncture SD) estimated based on the whole data set for 
experiment 1, and correspondingly for experiment 2, are presented together with the 
preanalytical SDs estimated in study II in Table 6. Correspondingly, the between-
venipuncture SDs are presented together in Table 7. 
Sensitivity analysis was done by excluding 8 samples with H-index > 40 for the 
analytes in experiment 2. The remaining samples had H-index ≤ 14. The 8 samples 
represented duplicates of 4 tubes collected from two venipunctures in two patients. 
Only the model estimates of LD were substantially influenced by excluding the high 
H-index samples (Table 6 and 7). 
Both in experiment 1 and 2, the distributions of test results were particularly positively 
skewed for the analytes ALP, ALT, creatinine, GGT, LD, and triglycerides, generally 
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with high test results from only one of the patients in the right tail. The sensitivity 
analysis showed that the model estimates were pretty robust against skewed data 
except for GGT (Table 6 and 7). Generally the CIs were somewhat broader when 
keeping the high values, but this only slightly affected the model estimates. Some 
measurement repeatability SDs were on the other hand reduced by excluding the high 
values (Table 3, Paper III). 
4.2.3 Preanalytical SDs  
Table 6 presents the preanalytical SDs (excluding between-venipuncture SD) (95% CI) 
estimated in study II, and in experiment 1 and 2 in study III. The CIs of the 
preanalytical SDs overlapped for 17 of 21 analytes. For creatinine, glucose and LD, 
the preanalytical SDs were significantly lower for the optimally treated samples (study 
II) compared with one or both of the estimates from study III. But when excluding 
samples with H-index>40 for LD (experiment 2, Paper III), the preanalytical SD in 
experiment 2 was similar to the preanalytical SD estimated for the optimally handled 
samples. Calcium was the only analyte showing higher preanalytical SD for the 
optimally treated samples.  
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Table 6. Comparison of the preanalytical SDs (excluding between-venipuncture SD) 
estimated in study II and III. 
 Preanalytical SDs  (excluding between-venipuncture SD) (95% CI) 
Analytes Study IIa                            Study IIIb             
(experiment 1) 
 
Study IIIc             
(experiment 2) 
Albumin, g/L 0.38 (0.31 – 0.45) 0.28 (0.23–0.33) 0.31 (0.26–0.36) 
ALP, U/L 0.64 (0.54 – 0.76) 0.37 (0.23–0.59) 0.52 (0.44–0.60) 
ALT, U/L 0.32 (0.094 – 1.076) 0.24 (0.039–1.42) 0.19 (0.029–1.20)d 
Bilirubin, μmol/L Not  analysed 0.069 (0.040–0.12) 0.086 (0.047–0.16) 
Calcium, mmol/L 0.012 (0.010 - 0.016) 0.0071 (0.0053–0.0095) 0.0084 (0.0068–0.010) 
Cholesterol, mmol/L 0.048 (0.039 – 0.060) 0.030 (0.022–0.041) 0.031 (0.024–0.040) 
CK, U/L 1.02 (0.85 – 1.23) 0.89 (0.75–1.07) 1.13 (0.98–1.30) 
Creatinine, μmol/L 0.58 (0.46 – 0.72) 0.66 (0.55–0.80) 0.94 (0.80–1.10) 
Folate, mmol/L Not analysed 0.17 (0.052–0.58) 0.28 (0.17–0.45) 
GGT, U/L 0.24 (0.13 – 0.46) 0.50 (0.098–2.55) 
0.24 (0.18–0.32)e 
0.52 (0.44–0.62) 
0.27 (0.20–0.36)f 
 
Glucose, mmol/L 0.07 (0.06 – 0.08) 0.097 (0.086–0.11) 0.10 (0.087–0.11) 
HDL-C, mmol/L 0.014 (0.010 – 0.018) 0.011 (0.0050–0.024) 0.0094 (0.0079–0.011) 
Iron, μmol/L Not analysed 0.11 (0.090–0.13) 0.14 (0.12–0.17) 
LD, U/L 3.2 (2.8 – 3.7) 5.2 (4.6–5.8) 4.4 (3.9–4.9) 
2.5 (2.2–2.8)g 
 
Magnesium, mmol/L 0.004 (0.002 – 0.008) 0.0011 (0.000036–0.0082) 0.0021 (0.0010–0.0044) 
Phosphate, mmol/L Not analysed 0.0059 (0.0046–0.0075) 0.0069 (0.0057–0.0082) 
Potassium, mmol/L 0.092 (0.080 – 0.11) 0.072 (0.065–0.081) 0.080 (0.072–0.090) 
Sodium, mmol/L 0.26 (0.14 – 0.47)d Instabilityh 0.16 (0.082–0.32) 
Total protein, g/L Not analysed 0.40 (0.32–0.50) 0.52 (0.45–0.60) 
Triglycerides, mmol/L 0.011 (0.010 – 0.014) 0.0087 (0.0057–0.013) 0.013 (0.011–0.015) 
Uric acid, μmol/L Not analysed 0.33 (0.049–2.25) 0.63 (0.42–0.95) 
a Optimally treated SST and RST tubes (whole data set). 
b Samples transported by pneumatic tube system and manual delivery (whole data set, experiment 1).                                                                        
c Blood collected with butterfly and green needles, and optimally and sub-optimally mixed (whole data set, experiment 2).                                      
d Because of wide 95% CIs, the between-venipuncture and preanalytical SD were combined to a common estimate. 
e High values of about 1495 U/L from one patients, were excluded. 
f High values of about 743 U/L from one of the patients, were excluded. 
g 4 samples with H-index > 40 excluded in addition to the already 4 samples automatically excluded at the instrument. 
h Wide 95% CIs, and simplifying the model also caused instability. 
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4.2.4 Between-venipuncture SDs  
Table 7 presents the between-venipuncture SDs (95% CI) estimated in study II, and in 
experiment 1 and 2 in study III. For all of the analytes, except for glucose, the CIs of 
the between-venipuncture SDs were overlapping. For glucose, the between-
venipuncture SD in experiment 1 at 0.32 mmol/L (green needles were used in both 
arms), is significantly higher than the between-venipuncture SD in experiment 2 at 
0.15 mmol/L, where green needle was used in one arm and a butterfly needle in the 
other. For LD, the between-venipuncture SDs were overlapping when the high H-
index samples were excluded.  
57 
 
Table 7. Comparison of the between-venipuncture SDs estimated in study II and III. 
 Between-venipuncture SDs (95% CI) 
Analytes Study IIa                           
 
Study IIIb 
(experiment 1)                 
 
Study IIIc  
(experiment 2)  
Albumin, g/L 0.47 (0.32 – 0.69) 0.48 (0.36–0.64)  0.38 (0.27–0.53) 
ALP, U/L 0.87 (0.59 – 1.27) 0.68 (0.49–0.95) 0.70 (0.51–0.95) 
ALT, U/L 0.47 (0.26 – 0.86) 0.17 (0.020–1.4) 0.19 (0.029–1.20)d 
Bilirubin, μmol/L Not  analysed 0.14 (0.10–0.20) 0.10 (0.061–0.17) 
Calcium, mmol/L 0.012 (0.010 - 0.019) 0.010 (0.0074–0.014) 0.0099 (0.0069–0.014) 
Cholesterol, mmol/L 0.071 (0.049 – 0.104) 0.050 (0.037–0.069)  0.058 (0.043–0.079) 
CK, U/L 1.51 (1.04 – 2.19) 0.92 (0.65–1.30) 1.09 (0.75–1.58) 
Creatinine, μmol/L 0.90 (0.62 – 1.31) 1.49 (1.12–1.97) 1.61 (1.20–2.16) 
Folate, mmol/L Not analysed 0.11 (0.019–0.67) 0.14 (0.036–0.56) 
GGT, U/L 0.42 (0.28 – 0.65) 0.83 (0.47–1.47)               
0.24 (0.15–0.37)e 
0.69 (0.50–0.95)                  
0.26 (0.16–0.41)f 
 
Glucose, mmol/L 0.20 (0.14 – 0.27) 0.32 (0.24–0.41) 0.15 (0.11–0.21) 
HDL-C, mmol/L 0.022 (0.015 – 0.032) 0.017 (0.011–0.026) 0.014 (0.010–0.019) 
Iron, μmol/L Not analysed 0.16 (0.12–0.22) 0.18 (0.13–0.26) 
LD, U/L 2.4 (1.5 – 3.9) 2.1 (1.1–4.2) 4.8 (3.5–6.6)                    
2.7 (1.9–3.7)g 
 
Magnesium, mmol/L 0.004 (0.002 – 0.008) 0.0049 (0.0035–0.0068) 0.0047 (0.0033–0.0065) 
Phosphate, mmol/L Not analysed 0.0080 (0.0058–0.011) 0.012 (0.0090–0.016) 
Potassium, mmol/L 0.075 (0.048 – 0.12) 0.094 (0.070–0.13) 0.067 (0.046–0.096) 
Sodium, mmol/L 0.26 (0.14 – 0.47)d Instabilityh 0.21 (0.13–0.34) 
Total protein, g/L Not analysed 0.85 (0.63–1.13) 0.66 (0.48–0.90) 
Triglycerides, mmol/L 0.016 (0.011 – 0.024) 0.013 (0.0088–0.018) 0.018 (0.013–0.025) 
Uric acid, μmol/L Not analysed 1.13 (0.81–1.59) 0.76 (0.50–1.15) 
a Optimally treated SST and RST tubes. Green needles were used in both arms. 
b Samples transported by pneumatic tube system and manual delivery. Green needles were used in both arms. 
c Tubes collected with butterfly and green needles, and optimally and sub-optimally mixed blood samples.           
d Because of wide 95% CIs, the between-venipuncture and preanalytical SD were combined.                                 
e High values of about 1495 U/L from one patients, were excluded. 
f High values of about 743 U/L from one of the patients, were excluded. 
g 4 samples with H-index > 40 excluded in addition to the already 4 automatically excluded at the instrument.          
h Wide 95% CIs, and simplifying the model also caused instability. 
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4.2.5 The width of confidence intervals  
The width of the CIs for the random effects in study II 
Figure 6 presents the between-venipuncture SD, the preanalytical SD, and the 
measurement repeatability SD including the 95% CIs estimated in study II. The figure 
shows that the measurement repeatability SDs had the narrowest CIs, and the between-
venipuncture SDs the broadest CIs for 11 of the 14 analytes.  
 
 
 
Figure 6. The figure presents, in respective order, the between-venipuncture SD, the 
preanalytical SD, and the measurement repeatability SD including 95% CIs estimated 
in study II. The vertical axis displays the size of the SDs (log scale).  
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Comparison of the width of the CIs for preanalytical SDs in study II and III 
Table 8 presents some examples on the relative width of the 95% CIs of the 
preanalytical SDs (excluding between-venipuncture SD) in study II and III. The 
relative width of the CIs is calculated as (the data from albumin in study II is used as 
example): (0.45–0.31) / 0.38 · 100 % = 37% 
 
Table 8. Relative width of the 95% CIs for the preanalytical SDs (excluding between-
venipuncture SD) in study II and III for five analytes. 
 Preanalytical SDs (excluding between-venipuncture) (95% CI)                             
Relative width of the CIs 
Analytes Study IIa                                   Study IIIb               
(experiment 1)  
Study IIIb                   
(experiment 2)  
Albumin, g/L 0.38 (0.31– 0.45) 0.28 (0.23–0.33) 0.31 (0.26–0.36) 
Relative width 37% 36% 32% 
Creatinine, μmol/L 0.58 (0.46 – 0.72) 0.66 (0.55–0.80) 0.94 (0.80–1.10) 
Relative width 45% 38% 32% 
Glucose, mmol/L 0.07 (0.06–0.08) 0.097 (0.086–0.11) 0.10 (0.087–0.11) 
Relative width 29% 25% 23% 
LD, U/L 3.2 (2.8– 3.7) 5.2 (4.6–5.8) 4.4 (3.9–4.9) 
2.5 (2.2–2.8)a 
Relative width 28% 23% 23 %                                 
24%c 
Potassium 0.092 (0.080 – 0.11) 0.072 (0.065–0.081) 0.080 (0.072–0.090) 
Relative width 33% 22% 23% 
a Study II included n=20, healthy volunteers                                                                                                                                    
b Study III included n=30 patients in experiment 1 and correspondingly in experiment 2                                                             
c 4 samples with H-index > 40 excluded in addition to the already 4 automatically excluded at the instrument. 
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4.3 Biases compared with quality specifications  
In order to evaluate the size of the biases in the studies, the combined biases from the 
uncertainty budgets (study I), and the statistically significant biases (95% CI) from 
study II and III, are compared with the desirable quality specifications for analytical 
bias derived from biological variation (39) (Table 9). All biases, except for glucose, 
were within the quality specifications. For glucose, the combined bias in the 
uncertainty budget at -0.15 mmol/L, and the bias between SST vs RST at -0.16 
mmol/L, was falling outside the quality specification at 0.11 mmol/L.  
 
Table 9. Comparison of the combined biases from the uncertainty budgets (study I), 
and the statistically significant biases (95% CI) in study II and III with desirable 
quality specifications for analytical bias derived from biological variation.  
Analytes Different comparisons Meana Biases (95% CI) Qual. 
spec. %b 
Qual- 
spec. abs. 
valuec 
Albumin, g/L SST vs RST 46.1  0.16 (0.016 to 0.29) 1.3 0.60  
Calcium,mmol/L Uncertainty budget 2.40 -0.011  0.8 0.019 
 SST vs RST 2.40  0.013 (0.0079 to 0.018) 0.8 0.019  
 Butterfly vs green 2.33  -0.0072 (-0.012 to -0.0012) 0.8 0.019  
CK, U/L Butterfly vs green 107  -0.75 (-1.42 to -0.075) 11.5 12.3  
Cholesterol,mmol/L SST vs RST 5.23  0.025 (0.0060 to 0.045) 4.0 0.21  
Creatinine, μmol/L Uncertainty budget 100d 0.5  4.0 4.0 
Glucose, mmol/L Uncertainty budget 5.2 -0.15  2.2 0.11 
 SST vs RST 5.2  -0.16 (-0.18 to -0.13) 2.2 0.11  
Iron, μmol/L Suboptimal vs optimal 
mixingg 
16.9  0.065 (0.016 to 0.11) 8.8 1.49  
LD, U/L SST vs RST 177.3  1.8 (0.8 to 2.9) 4.3 7.6  
 Pneumatic vs manual 210  4.5 (3.1 to 5.8) 4.3 9.0  
 Butterfly vs green 186  -1.6 (-3.2 to -0.021) 4.3 8.0  
Magnesium, mmol/L Uncertainty budget 0.85 0.006  1.8 0.015 
 SST vs RST 0.85  0.005 (0.003 to 0.008) 1.8 0.015  
 Pneumatic vs manual 0.80  0.0021 (0.00074 to 0.0035) 1.8 0.014  
Potassium, mmol/L SST vs RST 4.38  0.039 (0.010 to 0.068) 1.8 0.079  
a Mean of the test results in each study. Uncertainty budgets: The mean from one of the other projects are used.                                 
b Desirable quality specifications (%) for analytical bias (39).  
c The quality specifications are calculated from % to absolute values based on the mean in each study.   
d For creatinine, 100 μmol/L was used to calculate the limit of quality specification. 
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4.4 Combining bias and uncertainty 
4.4.1 Mean squared error budget 
Table 10 presents the calculation of the mean squared error (MSE) based on the 
combined bias and variance from the uncertainty budget (Table 2, Paper I). 
MSE = bias2 + SD2    
RMSE = √MSE     
Measured value ± 2· RMSE give the preanalytical uncertainty interval. The 
preanalytical uncertainty intervals do not include the analytical SDs.  
                                                                                                                                                                  
Table 10. Calculation of the MSE and the preanalytical uncertainty interval, based on 
the combined bias and variance from the uncertainty budget for each analyte. 
Analytes Combined    
biasa 
Combined 
varianceb 
MSEc RMSEd Preanalytical 
uncertainty intervale 
Calcium, mmol/L -0.011 0.00033 0.000452 0.0213 ± 0.04 mmol/L 
Creatinine, μmol/L 0.5 3.28 3.53 1.88 ± 3.8 μmol/L 
Glucose, mmol/L -0.15 0.017 0.0395 0.20 ± 0.4 mmol/L 
Magnesium, mmol/L 0.006 0.00066 0.000695 0.026 ± 0.05 mmol/L 
a Combined bias from the uncertainty budget (Table 2, Paper I)                                                                                                        
b Combined variance from the uncertainty budget (Table 2, Paper I)                                                                                                      
c MSE is defined as the expected squared deviation from a reference value, or a true value. MSE = bias2 + SD2                                 
d RMSE = √MSE                                                                                                                                                                                               
e The preanalytical uncertainty interval is ± 2· RMSE 
 
4.4.2 Recalculation of bias to random variation, an example  
For glucose, the estimated mean difference between transporting samples with a 
pneumatic tube system vs manual delivery was 0.025 mmol/L (Table 1, Paper III). As 
an example, we presume that 42% of the samples are transported by the pneumatic 
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tube system. The bias at 0.025 mmol/L can be recalculated to random variation based 
on the probability for transporting the samples by the pneumatic tube system: 
Transport type Pneumatic tube system Manual delivery 
Probability 0.42 0.58 
E (A|transport type) a + 0.025 a 
 
where “a” is determined by the fixed effects for the other covariates. 
A = measured concentration of the analyte 
 
Then, by standard formulas for double expectation and variance, 
EA = EE (A|transport type) = 0.42 · (a + 0.025) + 0.58 · a = a + 0.42 · 0.025 
EA2 = 0.42 · (a + 0.025)2 + 0.58 · a2 = a2 + 2 · 0.42 · 0.025 · a + 0.42 · 0.0252  
Var(A) = (EA2) – (EA)2 =                                                                                                
a2 + 2·0.42·0.025·a + (0.42·0.0252) – (a2 + 2·a·0.42·0.025 + 0.422·0.0252) =            
0.42 · 0.025   2 –  0.42  · 0.025 = 0.025  ·0.42 (1-0.42) = 0.000152 2 2  
SD(A) = √Var (A) = 0.025 √ [0.42 (1-0.42)] = 0.012 mmol/L 
 
Similar recalculations are planned to be elaborated in further work. 
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5. DISCUSSION 
In this thesis and its associated papers we aimed to establish a modelling framework 
for estimating preanalytical uncertainty. Knowledge of the relative magnitude of 
uncertainty sources provide possibilities for modifying the measurement systems to 
improve the quality of results (2). In study I, the “bottom-up” approach, a model for an 
uncertainty budget was established, based on the biases from paired data between the 
standard method for handling blood samples and current practice. The model consisted 
of five subprojects examining one uncertainty source at a time. But the model did not 
determine the uncertainty in the optimal practice itself.  
In study II, the “top-down” approach, the phlebotomy and sample handling were 
performed optimally according to existing standards, and by using linear mixed-effects 
models (46), the minimal preanalytical uncertainty in optimal practice was estimated. 
This minimal preanalytical uncertainty may be used as a standard of reference for 
evaluation of preanalytical uncertainty in current practice. Linear mixed-effects 
models constitute a well-developed and suitable method to identify different sources of 
variation (46). The model allows clustered data, where both random variation and 
systematic deviations are estimated, and the model assumptions are made clear.  
Study III involved further use of linear mixed-effects models, and the number of 
preanalytical variables was expanded. We wanted to examine whether specific, 
preanalytical treatments within current practice would increase the preanalytical 
variation, and bias test results compared with optimal treatment. Literature search did 
not lead to similar studies using linear mixed-effects models within the preanalytical 
field, indicating that this thesis include models that are quite new within the field. 
In the following, the specific findings in each paper, the models and methodological 
considerations will be discussed. Further on, the preanalytical (excluding the between-
venipuncture) and the between-venipuncture variations estimated in study II and III 
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are compared to each other, followed by a discussion on the treatment of biases and 
the concept of traceability in preanalytical phase. 
5.1 Paper I  
5.1.1 Main results 
Paired data are easy to attain, and are often available in minor projects. For all the 
different preanalytical uncertainty sources in the budget, standard methods were 
defined. For the continuously distributed uncertainty sources, the alternative methods 
were defined as the maximal deviations within current practice. E.g. clotting time can 
attain any value in some interval, and represents a continuously distributed uncertainty 
source. Using different kinds of blood tubes involves a finite number of alternative 
methods, and represents a categorically distributed uncertainty source. The uncertainty 
contribution from each uncertainty source is easily accessible in the budget (Table 2, 
Paper I), and solutions can be made directly to reduce the uncertainty. Most important 
is to reduce the uncertainty from any great contributors, but also several minor 
contributions can be summed up to give a considerable contribution.  
Generally, uncertainty budgets are established from existing knowledge, and should 
predict the combined uncertainty of future test results (69). It is claimed that the 
uncertainty budgets should be verified, because uncertainty components may have 
been overlooked, uncertainty may have been incorrectly estimated, or changes may 
have occurred (69). Because of medical consequenses, the combined bias, from 
summing up the individual biases, should not fall outside defined quality 
specifications. 
When comparing the combined biases in the uncertainty budget with quality 
specifications (Table 9), only glucose at -0.15 mmol/L was falling outside the quality 
specifications for analytical bias (39). Prolonged clotting and storage time were the 
greatest contributors to the uncertainty budget, and the concentration of glucose 
65 
 
probably decreased because of glycolysis (54). Because of a variety of experimental 
designs, it may be difficult to interpret information on stability from the literature (70). 
Nevertheless, a study showed that glucose decreased, and exceeded the combined 
analytical and clinical acceptability limit, after storing the blood tubes at 32 oC in 3 
hours compared with the values from separation of the sera from the clot within 30 
min (70).  
5.1.2 Methodological considerations 
Detailed knowledge of the nature of the component and of the sample handling is 
essential both for designing the study, and for calculating the uncertainty. In practice, 
the alternative methods are used to a variable extent. The probability distributions  
seem suitable for the uncertainty sources included in the budget, because the countable 
alternative treatments characterize the categorically distributed uncertainty sources, 
while the attainment of any value within an interval, characterize the continuously 
distributed uncertainty sources.  
When the probabilities of e.g. using the alternative blood tubes changes, or if the 
standard blood tube is exchanged to another tube, new calculations of the bias have to 
be done. At the laboratory there are usually several instruments analysing the same 
analyte. Continuity of medical care requires that the comparability of test results 
produced by different instruments is verified periodically (71). It is recommended to 
define one instrument as the standard instrument, and the other instruments should 
then be calibrated up to the standard instrument, in order to attain the same analytical 
accuracy. There still may be a small bias between the instruments, and the bias could 
occasionally vary. In study I, this bias was a part of the preanalytical uncertainty 
budget. Because the mean and SD of differences in the paired data between the 
standard method and the alternative method are fundamental in the calculations, it is 
important that they are representative for the whole range of test results.  
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For continuous uncertainty sources, the assumptions of linearity of the means and SDs 
of differences have not been empirically justified. Because the interval defined for 
each continuously distributed uncertainty source is not especially broad, and assuming 
that the bias at the maximal distance is highest, the estimated biases are probably not 
overestimated. The assumption of independence, when summing up the expected 
individual differences and variances seems reasonable, because the uncertainty sources 
are probably not related to each other, and therefore they are assumed not to influence 
on each other. 
5.2 Paper II and III 
5.2.1 Main results  
Good standardization is a prerequisite for high power and accurate model estimates. 
The analysing methods have good analytical precision and trueness, ensuring the 
reliability and the precision of the model estimates. Both study II and III were well 
standardized in the sense that randomization was carried out at all levels, e.g. what 
type of needle should be used on what arm, the order of tubes during the collection, the 
choice of tubes that should be transported in the pneumatic tube system, and during 
analyses. The phlebotomy time was supervised, the clotting time was held within 
acceptable limits, and the time after centrifugation until analysis was supervised. By 
analyzing the H-index in all samples, the preanalytical quality of the samples was 
supervised. Examining many analytes, as in our studies II and III, is also a strength, 
and the finding of small significant differences indicates that the number of 
observations was acceptable. However, there will always be a certain probability of 
finding significant differences by chance in studies involving many analytes, repeated 
measurements and statistical tests.  
In study II, the optimal handling of the SST tubes included 30 min clotting time, while 
for the RST tubes the clotting time was 5 min. Due to shorter clotting time for the 
RSTs, serum was separated from the erythrocytes approximately 25 min before the 
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SSTs, and this may explain why the H-index was significantly higher in the SST tubes 
compared with the RST tubes. Hemolysis may also be the reason why potassium, LD 
and magnesium showed a significantly higher concentration in the SSTs, and glucose a 
significantly lower concentration, probably because of glycolysis (Table 1, Paper II). 
Thus, the choice of correct tube is important to minimize the preanalytical uncertainty, 
even when following an optimal protocol.  
Table 5 shows that preanalytical uncertainty including the between-venipuncture 
variation is a substantial contributor to the total uncertainty of test results, although the 
blood samples were treated optimally based on current guidelines. The uncertainty 
increased nearly 300% for glucose, and potassium, when the preanalytical and the 
between-venipuncture variations were included in the uncertainty calculations, 
compared to the measurement repeatability. Thus, those variations are shown not to be 
negligible even for optimally handled samples.  
A study, which included the uncertainty from specimen collection, delay in treatment, 
and transportation, the preanalytical uncertainty for cholesterol was estimated to 0.7%, 
for albumin 4.5% and potassium 6.6%, and the combined preanalytical and analytical 
uncertainty was 4.1%, 6.5%, and 6.8%, respectively (27). In our results on 
preanalytical variation including the between-venipuncture variation for optimally 
treated samples (Table 5), albumin and potassium were estimated much lower. A study 
by Fuentes-Arderiu et al. on premetrological variation estimated by using paired data, 
where the variance of the differences were adjusted for analytical variation, included 
uncertainty from venipuncturing both arms, use of different phlebotomists, and 
different clotting time (23). In that study, the premetrological variation was estimated 
to be 3.2% for glucose, for albumin 1.3%, calcium 0.7%, and potassium 3.1% (23). 
Compared with our results shown in Table 5, the estimates are very similar. In an 
additional study, the 95% uncertainty interval of a measurement result on fasting 
plasma glucose at 5.9 mmol/L was estimated to be 5.1 – 6.6 mmol/L (26). The interval 
included uncertainty from patient preparation, position, sampling and measurement 
procedure. In our study II, the combined SD of preanalytical and analytical SD for 
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optimally handled samples for glucose was 0.22 mmol/L (Table 3, Paper II), i.e. the 
95% uncertainty interval is about ± 0.44 mmol/L. It seems reasonable that our estimate 
is different, both because our uncertainty interval includes fewer uncertainty sources, 
and because of the difference in methods for calculating the uncertainty. In the study 
by Kallner et al. plausible intervals were assumed and the uncertainty estimated from 
rectangular distributions (26). 
The results obtained from any model are estimates, not the truth, and estimates may 
differ depending on underlying assumptions. The design of the studies in the cited 
papers, and the differences in the preanalytical variations estimated in the different 
studies, may indicate that there are a need for clear descriptions of what uncertainty 
sources are included, what statistical methods are used, and what the assumptions are. 
This is needed, particularly, if estimated preanalytical uncertainty is to be transferable 
to other laboratories. This work is a response to a need for a standardized statistical 
method for estimating preanalytical uncertainty. 
In study III, transporting blood tubes by a pneumatic tube system resulted in 
significantly higher values for LD and magnesium (Table 1, Paper III), probably due 
to hemolysis or leakage through the cell membrane, as the concentration of LD (62) 
and magnesium (72) are higher in erythrocytes than in serum. However, the higher 
preanalytical SD for glucose for blood tubes transported in a pneumatic tube system 
compared with manual delivery (Table 2, Paper III), is difficult to explain. The 
shaking and speed of the tubes during the pneumatic tube transport, may increase the 
glycolysis in some tubes. It may be difficult to transfer research results from one 
pneumatic tube system to another, because of different technical characteristics of the 
pneumatic tube system, such as speed, length and time of transport.  
Because the preanalytical SDs estimated separately for the paired treatments (Table 2, 
Paper III) showed minor differences for only a few analytes, the random effects 
presented in Table 3 and 4 in Paper III, are estimated based on the whole data set 
separately for each experiment. For most analytes, the preanalytical SDs were about 
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the same in both experiments, indicating that the preanalytical variation is little 
influenced by the different preanalytical treatments carried out in study III. 
When using butterfly needles, LD was significantly lower -1.6 U/L (P=0.047) 
(samples with H-index > 40 were excluded) compared with using green needles. The 
opposite might be expected, because using butterfly needles is associated with higher 
pressure of the blood, which may result in hemolysis (73). On the other hand, using 
butterfly needles may give a more stable phlebotomy, and a more gentle cut in the vein 
compared with the green, straight needles. Mixing the blood tubes by only one 
inversion compared with recommended mixing of 5-6 inversions, did not influence the 
test results. In general, the statistically significant systematic effects found between 
suboptimal vs optimal treatment in Paper III were too small to have any clinical 
impact.  
5.2.2 Preanalytical SDs  
The preanalytical SD (excluding venipuncture SD) may be caused by variations in 
filling of the tubes, sample mixing, clotting time, centrifugal force, and extent of 
hemolysis. It may be expected that the optimally handled samples in study II have less 
preanalytical SD than the samples in study III, which included both optimally and 
suboptimally treated samples (Table 6). Lack of significant difference may indicate 
that the preanalytical SDs based on optimally treated samples, are reasonable estimates 
of preanalytical variation, independent of the preanalytical treatment shown here. 
There are several conditions that may influence both the magnitude of the SDs, and the 
width of the CIs, and it is difficult to explain the difference or the similarity in 
preanalytical SDs between the studies. The preanalytical treatment, whether healthy 
individuals or patients are included, number of participants, concentration and 
distribution of the test results, are factors that may influence the magnitude of the 
preanalytical SDs.  
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Of the measured analytes, seventeen of 21 analytes had overlapping preanalytical SDs 
(Table 6). For calcium, the only analyte showing higher preanalytical SD for the 
optimally treated samples, the concentration of calcium was somewhat higher in the 
samples in study II (Table 3, Paper II) than in study III (Table 3 and 4, Paper III), 
which may influence on the magnitude of the preanalytical SD. The slightly lower 
preanalytical SD for glucose at optimal treatment in study II may be caused by less 
variation in the test results, because of a more perspicuous and standardized treatment, 
than the different treatments in study III. However, the difference in preanalytical SD 
is too small to have any clinical significance. For LD, it is difficult to compare the 
preanalytical SDs between the studies, because LD is sensitive for hemolysis, and 
hemolysis may be caused by the phlebotomy and by the specific preanalytical 
treatment. Excluding some samples with H-index > 40 in experiment 2 seems realistic, 
because the remaining samples then had H-index less than 14.  
The test results in study III were somewhat more skewed than the test results in study 
II. More heterogeneous test results may give wider CIs. However, the number of 
participants was higher in study III than in study II, that may compensate for the 
skewed data. Thus, there are no indications that the preanalytical SDs are higher in 
samples from patients than in blood samples collected on healthy individuals. 
Consequently, estimating the minimal preanalytical uncertainty by analyzing optimally 
treated blood samples from healthy individuals, may give an unbiased estimate of the 
general preanalytical variation of blood samples, collected in an outpatient clinic and 
suboptimally treated as shown here. Transporting the samples by a pneumatic tube 
system, collecting blood using butterfly needles, and suboptimal mixing, do not 
substantially influence the size of the preanalytical uncertainty.  
Regarding the design of the study, it may influence on the size of the random and fixed 
effects. Blood was collected in accordance with current practice into four tubes from 
each arm. The mean venipuncture time for both arms was about 3 min in study II, and 
3.5 min in study III which is considered acceptable. If only two blood tubes were 
collected from each arm, we would probably need a higher number of participants, in 
71 
 
order to achieve similar narrow CIs. Contrary, collection of e.g. six blood tubes from 
each arm, would be very different from current practice. By letting several medical 
technicians perform the phlebotomy instead of only one as in study II and III, the 
estimates of both the preanalytical and the between-venipuncture SDs would probably 
be higher. Both variations in filling volume of the blood tubes, in mixing of the blood 
tubes, clotting time, and degree of hemolysis, would be influenced by the medical 
technician. In contrast, variation in centrifugation time, storage time before analysis, 
and room temperature, are procedures not dependent on the phlebotomist.  
5.2.3 Between-venipuncture SDs  
The between-venipuncture variation turned out to be somewhat higher than the 
preanalytical variation (excluding the between-venipuncture variation) for several 
analytes, and especially for glucose (Figure 1 and Table 3 in Paper II, and Table 3 and 
4 in Paper III). Factors that may cause between-venipuncture variation are variation in 
blood flow, difference in muscle strenght, blood pressure, the position of the arm, the 
tightness of tourniquet, and the depth and cut of the phlebotomy. Even though the 
patients in the out-patient clinic often were more difficult to venipuncture than the 
healthy individual, because of more frequent phlebotomies, fragile veins and 
hematoma, and difficulties in finding the veins, glucose was the only analyte where the 
CIs of the between-venipuncture SDs were not overlapping (experiment 1 and 2 in 
study III) (Table 7). Using butterfly needles as in experiment 2, or venipuncturing 
healthy individuals (study II), gives the lowest between-venipuncture variation for 
glucose, which may be caused by a more smooth phlebotomy. 
5.2.4 Methodological considerations 
The width of the CIs  
The estimates of random variation neither increase nor decrease systematically with 
the number of participants, but the confidence intervals are narrower for larger 
samples. To decrease the preanalytical SDs, the practice has to improve or change. To 
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decrease the uncertainty (the width of the CIs) of the preanalytical SDs, the number of 
participants has to increase. The acceptable magnitude of the preanalytical SD and 
width of the 95% CI, depend on the analyte and clinical use. Glucose needs accurate 
estimates because the parameter is used in the diagnosis of diabetes. Reducing the 
relative width of the CI for preanalytical SD for glucose from 29% to 23-25% when 
increasing the number of participants from 20 to 30 in study III, does not seem very 
decisive for the calculation of the total uncertainty (Table 8).  
When the preanalytical SDs were estimated separately for each of the paired 
treatments in experiment 2, for e.g. the green needles (Table 2, Paper III), the test 
results from both optimally and suboptimally mixed tubes were included. If e.g. the 
preanalytical SDs for the tubes collected by the green needles should be estimated 
based on only the results from the optimally mixed tubes, would have required 
dividing the dataset in experiment 2 in four parts. Because of the risk of losing power, 
resulting in unstable or wider CIs, we chose to divide the dataset in only two parts. On 
the other hand, there may be fewer assumptions that can be wrong in more isolated 
situations. The possibility for separate modeling in different clusters is higher in a 
large than in a small data set. When the preanalytical SDs were estimated separately 
for the optimally treated and the suboptimally treated group (Table 2, Paper III), the 
number of unstable 95% CIs were higher, than when using the whole data set (Table 3 
and 4, Paper III).   
The reason why the widths of the CIs in most cases are broader for the between-
venipuncture SDs (Figure 6) may be that the estimates are based on two venipunctures 
from each participant, while the preanalytical SDs are based on test results from 4 
tubes from each arm, and the measurement repeatability SDs are calculated based on 
results from duplicates of all tubes. The width of the between-venipuncture CIs would 
probably be somewhat reduced if e.g. four venipunctures were performed on the same 
individual. 
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Skewness 
It is important to know the distribution of the test results in order to obtain correct 
estimates. Excluding the high results in the tail (sensitivity analysis), gives estimates 
based on less skewed test results. Comparing these estimates with the estimates from 
the main analysis, which included all the data (as shown in paper III), demonstrate that 
linear mixed-effects models are pretty robust against skewed data. The estimates from 
the sensitivity analysis are mostly comparable. The high test results should not be 
removed from the main analysis, because they may be part of the variables’ natural 
variation.  
The model estimates in study II and III will be applicable to the concentration area 
where the majority of the test results in the studies were. Thus, in concentration areas 
where there are few data, as in the right tail of the distribution (study III), the estimates 
will be less applicable. The estimates will not be applicable for concentration areas 
outside of the area that was the basis for the model.  
5.3 Treatment of biases 
If a specified treatment gives a well-defined bias and the probability for using the 
alternative treatment is known, a correction for bias is possible. Though, making 
corrections is demanding, and requires a high degree of security of the estimated bias, 
including narrow CIs estimated from a large data set. It will require that the routine 
practice is similar to the research practice, where the bias was estimated, and standard 
procedures must be followed. Preanalytical handling will often create biases that are 
unverifiable and unpredictable, and therefore not suitable for corrections.  
If EQA reveals an analytical bias which may influence the trueness, common practice 
is, if possible, to eliminate the bias, in order to sustain the stability of the accuracy of 
the method, and the reliability of the reference intervals. It has been discussed whether 
non-significant analytical bias should be included in the uncertainty budget, because 
when the bias is non-significant, it is assumed that a procedure is unbiased (74). As a 
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result it was argued that a non-significant bias should be included in the uncertainty 
budget, when the uncertainty represents at least 30% of the overall uncertainty (74). 
As shown in the uncertainty budgets, the biases may also neutralize each other (Table 
2, Paper I).  
We have presented two cases for combining bias and uncertainty, 1) the MSE budget 
and 2) an example of recalculation of the bias estimated between ways of 
transportations, to random variation, by connecting the probability for transporting the 
samples by the pneumatic tube system. These recalculations are planned to be further 
elaborated.  
In parallel with the quality specifications for analytical performance, there should also 
be quality specifications for preanalytical performance. The demands on analytical 
performance derived from biological variation were stated to satisfy general medical 
needs (38). The biases for all analytes (study I, II, and III), except for glucose, were 
within the quality specifications. This indicates that, except for glucose, the existing 
practice at the laboratory using RST tubes, butterfly needles, pneumatic tube transport, 
and suboptimal mixing, is acceptable when evaluated against these quality 
specifications.  
When the analytical performance fulfils the analytical demands based on biological 
variation (5), we may experience that when preanalytical uncertainty is included, the 
demands are not fulfilled. There are guidelines for optimal preanalytical handling 
(6;13), and two models for estimating preanalytical uncertainty has been established in 
this work. The quality specifications should be revised to cover the total uncertainty, 
including both analytical and preanalytical uncertainty. 
Critical difference or the reference change value (RCV) is calculated in order to 
examine whether a specific change in serial test results from a patient, is caused by a 
change in the medical condition, or may be caused by the within-subject biological 
variability and the analytical imprecision of the method (5). The formula for the 
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calculation of RCV involves the analytical variation and the within-subject variation, 
while the preanalytical variation is considered negligible (5). Results from our studies 
may indicate that the RCV application should be revised by including the preanalytical 
variation. 
5.4 Traceability, trueness, accuracy  
EQA adds substantial value to the practice of laboratory medicine, and global 
standardization and harmonization of analytes are needed to support clinical practice 
(44). In EQA, the analytical accuracy is evaluated, not the preanalytical quality. 
Questionnaires are used in EQA to register the participants’ preanalytical practices or 
solutions on preanalytical problems (16). A working group on the preanalytical phase 
intends to identify some of the most critical elements in this phase, and to make 
recommendations on how to reduce the impact of the preanalytical phase (16).  
If we should transmit the concept of traceability from the analytical to the 
preanalytical field, evidence based guidelines such as the CLSI guidelines on 
recommended phlebotomy and preanalytical sample handling (6;13), can function as a 
reference method in preanalytical handling, similar to analytical calibrators that are 
traceable to a reference in the analytical field. Thus, preanalytical traceability would 
require estimating the preanalytical uncertainty for samples handled optimally, based 
on recommended guidelines, by using a valid statistical method. This will represent the 
preanalytical accuracy, the best practice with the minimal preanalytical uncertainty. 
Similar to analytical variation, the preanalytical uncertainty has to be monitored and 
verified. 
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6. MAIN CONCLUSIONS  
Two models for estimating preanalytical uncertainty have been established. By the 
“bottom-up” approach, the uncertainty for each uncertainty source has been estimated, 
and the individual expected biases and variances combined in an uncertainty budget. 
In the “top-down” approach, by using linear mixed-effects models, the total 
preanalytical variation within clustering levels of the data was estimated, together with 
the biases between different treatments. Both models are practical, and have limited 
and acceptable methodological assumptions. The model estimates are valid with 
acceptable size of most confidence intervals.  
Glucose was the only analyte falling outside the quality specifications for analytical 
bias, when the significant biases between different preanalytical treatments in Paper II 
and III, and the combined biases from the uncertainty budget in Paper I were 
compared with quality specifications. For glucose, the combined bias from the 
uncertainty budget (Paper I), and the mean difference between SST vs RST tubes 
(Paper II) was falling outside the quality specifications, with prolonged clotting and 
storage time as the greatest contributors to the uncertainty budget. This may have 
medical consequences. Choice of tube is especially important for glucose, and a 
standardized procedure is needed in order to reduce the preanalytical uncertainty for 
glucose.  
In Paper II, the preanalytical SDs (excluding the between-venipuncture SD) for LD 
and potassium for optimally treated samples, were significantly higher than the 
measurement repeatability SDs, but for glucose, the between-venipuncture SD was the 
dominant source of variation. The total uncertainty more than doubled, when the 
preanalytical SDs and the between-venipuncture SDs were added to the measurement 
repeatability for albumin, ALP, CK, glucose, LD, and potassium (Paper II).  
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In Paper III, the preanalytical SD for glucose for samples transported in the pneumatic 
tube system, was significantly higher than for samples manually delivered. Use of 
different needles and mixing methods gave no important effects.  
For most analytes, the preanalytical SDs estimated in study II and III, were about the 
same, indicating that the preanalytical variations are less influenced by different 
preanalytical handling, and by participants included in the studies. Consequently, the 
minimal preanalytical SDs for the analytes, based on optimal phlebotomy and handling 
of the blood tubes collected from healthy individuals, may be considered as a 
reasonable estimate of the preanalytical variation of blood samples, also for blood 
samples collected in an outpatient clinic, and suboptimally treated as shown. 
Overall, a standardized preanalytical handling procedure based on guidelines should 
be settled for each component. The estimation of the minimal preanalytical uncertainty 
based on optimal handling of the blood samples is important, especially for 
components where accurate estimates of the test results are needed in clinical practice. 
Establishing an uncertainty budget is especially important when using treatments 
alternative to optimal treatment. Estimation of preanalytical uncertainty may improve 
diagnostic quality and patient treatment. 
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7. FUTURE PERSPECTIVES 
Further work on recalculation of biases to random variation is planned.  
We would like to use linear mixed-effects models further in estimating the minimal 
preanalytical uncertainty for even more analytes, and also introduce new uncertainty 
sources such as e.g. posture during phlebotomy, and resting in a sitting position for 15 
min before phlebotomy. Preanalytical uncertainty may be estimated using samples 
from clinically relevant situations as e.g. heart patients, when testing on heart markers.  
The cause of the between-venipuncture variation should be elucidated by further 
research.  
Based on our models, it will be considered at our laboratory, to start the process 
writing a guideline, on how to estimate preanalytical uncertainty. Estimation of 
preanalytical uncertainty may be a part of the general method validation to improve 
the quality of the whole analysing process.  
Internationally, preanalytical traceability may be defined for each analyte, a stronger 
emphasis on standardization of preanalytical treatment may be needed, and quality 
specifications should be made for preanalytical uncertainty.  
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